

DN 96339375 PubMed ID: 9676753
 T1 Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
 AU Vocum D E; Solinger A M; Teaser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dalai B; Shen C D; Lipani J
 CS Department of Medicine, Arizona Health Sciences Center, Tucson 85724, USA.
 SO JOURNAL OF RHEUMATOLOGY, (1998 Jul) 25 (7) 1257-62.
 CY Journal code: 7501984. ISSN: 0315-162X.
 DT Canada
 (CLINICAL TRIAL)
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199809
 ED Entered STN: 19981008
 Last Updated on STN: 19981008
 Entered Medline: 19980929

L1 ANSWER 5 OF 63 MEDLINE
 AN 97339220 PubMed ID: 9191886
 DN A primetized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo
 T1 Characterization of a MAb (IDEC-CE9.1) to human CD4.
 AU Anderson D; Chambers K; Hanna N; Leonard J; Reif M; Newman R; Baldoni J; Dunleavy D; Reddy M; Sweet R; Truneh A
 CS IDEC Pharmaceuticals Corporation, San Diego, California 92121, USA.
 SO CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, (1997 Jun) 84 (1) 73-84.
 CY Journal code: 0356637. ISSN: 0090-1229.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199707
 ED Entered STN: 19970721
 Last Updated on STN: 19980206
 Entered Medline: 19970708

L1 ANSWER 6 OF 63 MEDLINE
 AN 97041345 PubMed ID: 8886616
 DN Disposition of metabolically radiolabeled CE9.1--a
 T1 macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4.
 AU Davis C B; Garver E M; Kwok D C; Urbanski J J
 CS Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
 SO DRUG METABOLISM AND DISPOSITION, (1996 Sep) 24 (9) 1032-7.
 CY Journal code: 9421550. ISSN: 0090-9556.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199702
 ED Entered STN: 19970227
 Last Updated on STN: 19970227
 Entered Medline: 19970212

L1 ANSWER 7 OF 63 CANCERLIT
 AN 199294090 CANCERLIT
 DN 99294090

T1 Flow cytometry in the preclinical development of biopharmaceuticals.
 AU Gossett K A; Narayanan P K; Williams D M; Gore E R; Hetzyk D J; Hart T K; Sellers T S
 CS SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. kent.gossett@spbrd.com
 SO TOXICOLOGIC PATHOLOGY, (1999). Vol. 27, No. 1, pp. 32-7.
 DT Journal code: TOX. ISSN: 0192-6233.
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 FS MEDL; L; Priority Journals
 LA English
 OS MEDLINE 99294090
 EM 199908

L1 ANSWER 8 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001274460 EMBASE
 T1 The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.
 AU Kon O.M.; Sihra B.S.; Loh L.C.; Barkans J.; Compton C.H.; Barnes N.C.; Larche M.; Kay A.B.
 CS Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LJ, United Kingdom
 SO European Respiratory Journal, (2001) 18/1 (45-52).
 Refs: 27
 ISSN: 0903-1936 CODEN: ERJOEI
 CY Switzerland
 DT Journal: Article
 FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 026 Immunology, Serology and Transplantation
 030 Pharmacology
 037 Drug Literature Index
 LA English
 SL English

L1 ANSWER 9 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2000377446 EMBASE
 T1 Chimeric human-simian anti-CD4 antibodies form crystalline high symmetry particles.
 AU Kuznetsov Yu.G.; Day J.; Newman R.; McPherson A.
 CS Yu.G. Kuznetsov, Department of Biochemistry, University of California, Irvine, CA 92697-3900, United States
 SO Journal of Structural Biology, (2000) 131/2 (108-115).
 Refs: 22
 ISSN: 1047-8477 CODEN: JSBIEM
 CY United States
 DT Journal: Article
 FS 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA English
 SL English

L1 ANSWER 10 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2000063910 EMBASE
 T1 Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required.
 AU Podolin P.L.; Webb E.F.; Reddy M.; Truneh A.; Griswold D.E.
 CS Dr. P.L. Podolin, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, United States
 SO Immunology, (2000) 99/2 (287-295).
 Refs: 44
 ISSN: 0019-2805 CODEN: IMMUDM
 CY United Kingdom

- DT Journal; Article
FS 026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English
- L1 ANSWER 11 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998328616 EMBASE
TI Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (Kelliximab) in chronic severe asthma.
AU Kon O.M.; Shira B.S.; Compton C.H.; Leonard T.B.; Kay A.B.; Barnes N.C.
CS Dr. N.C. Barnes, Department of Respiratory Medicine, London Chest Hospital, London E2 9JX, United Kingdom
SO Lancer, (3 Oct 1998) 352/9134 (1109-1113).
Refs: 24
ISSN: 0140-6736 CODEN: LANCNO
CY United Kingdom
DT Journal; Article
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
- L1 ANSWER 12 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998229584 EMBASE
TI Subcutaneous bioavailability of a PRIMATIZED(TM) IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4.
AU Davis C.B.; Bugelski P.J.
CS Dr. C.B. Davis, SmithKline Beecham Pharmaceuticals, Drug Metabolism and Pharmacokinetics, Mail Code UW2720, 709 Swedeland Road, King of Prussia, PA 19406, United States
SO Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, (1998) 5/2 (95-100).
Refs: 12
ISSN: 1071-7544 CODEN: DDELEB
CY United States
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
039 Pharmacy
LA English
SL English
- L1 ANSWER 13 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998228162 EMBASE
TI Clinical and immunologic effects of a PRIMATIZED(TM) anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial.
AU Yocum D.E.; Solinger A.M.; Tesser J.; Gluck O.; Cornett M.; O'Sullivan F.; Nordensson K.; Dallaire B.; Shen C.D.; Lipani J.
CS Dr. D.E. Yocum, AHSC, 1501 N. Campbell, Tucson, AZ 85724, United States
SO Journal of Rheumatology, (1998) 25/7 (1257-1262).
Refs: 32
ISSN: 0315-162X CODEN: JRHUA
CY Canada
DT Journal; Article
FS 031 Arthritis and Rheumatism
037 Drug Literature Index
- LA English
SL English
- L1 ANSWER 14 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998138658 EMBASE
TI Biological agents in rheumatoid arthritis: Which ones could be used in combination?
AU Lorenz H.-M.; Kalden J.R.
CS Dr. H.-M. Lorenz, Department of Medicine III, Inst. Clinical Immunol./Rheumatology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany. Hannes.Lorenz@med3.med.uni-erlangen.de
SO Biodrugs, (1998) 9/4 (303-324).
Refs: 130
ISSN: 1173-8804 CODEN: BIDRF4
CY New Zealand
DT Journal; General Review
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
033 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
- L1 ANSWER 15 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97209580 EMBASE
DN 1997209580
TI A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4.
AU Anderson D.; Chambers K.; Hanna N.; Leonard J.; Reff M.; Newman R.; Baldoni J.; Dunleavy D.; Reddy M.; Sweet R.; Truneh A.
CS R. Newman, IDEC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA 92121, United States
SO Clinical Immunology and Immunopathology, (1997) 84/1 (73-84).
Refs: 41
ISSN: 0090-1229 CODEN: CLIIAT
CY United States
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
LA English
SL English
- L1 ANSWER 16 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96288995 EMBASE
DN 1996288995
TI Disposition of metabolically radiolabeled CE9.1 - A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4.
AU Davis C.B.; Garver E.M.; Kwok D.C.; Urbanski J.J.
CS SmithKline Beecham Pharmaceuticals, Drug Metabolism and Pharmacokinetics, Mail Code UW2730, 709 Swedeland Road, King of Prussia, PA 19406, United States
SO Drug Metabolism and Disposition, (1996) 24/9 (1032-1037).
ISSN: 0090-9556 CODEN: DMSAI
CY United States
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L1 ANSWER 17 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:410273 BIOSIS
 DN PREV200100410273
 TI The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.
 AU Kon, O. M.; Sihra, B. S.; Loh, L. C.; Barkans, J.; Compton, C. H.; Barnes, N. C.; Latche, M.; Kay, A. B. (1)
 CS (1) Dept of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY UK
 SO European Respiratory Journal, (July, 2001) Vol. 18, No. 1, pp. 45-52.
 DT Article
 LA English
 SL English
 L1 ANSWER 18 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999:146171 BIOSIS
 DN PREV199900146171
 TI Flow cytometry in the preclinical development of biopharmaceuticals.
 AU Gossett, Kent A. (1); Narayanan, Padma K.; Williams, Donna M.; Gore, Elizabeth R.; Herzyk, Danuta J.; Hart, Timothy K.; Sellers, Teresa S. (1)
 CS (1) SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406 USA
 SO Toxicologic Pathology, (Jan.-Feb., 1999) Vol. 27, No. 1, pp. 32-37.
 DT Article
 LA English
 L1 ANSWER 19 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:320004 BIOSIS
 DN PREV199800320004
 TI Tight ligand binding affinities determined from thermodynamic linkage to temperature by titration calorimetry.
 AU Doyle, Michael L. (1); Hensley, Preston
 CS (1) Dep. Structural Biology, SmithKline Beecham Pharmaceutical, King of Prussia, PA 19406 USA
 SO Acers, G. K. [Editor]; Johnson, M. L. [Editor]. Methods in Enzymology, (1998) Vol. 295, pp. 88-99. Methods in Enzymology; Energetics of biological macromolecules, Part B. Publisher: Academic Press, Inc. 1250 Sixth Ave., San Diego, California 92101, USA.
 DT Book
 LA English
 L1 ANSWER 20 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:485409 BIOSIS
 DN PREV199800485409
 TI Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma.
 AU Kon, O. M.; Sihra, Bhupinder S.; Compton, Christopher H.; Leonard, Thomas B.; Kay, A. Barry; Barnes, Neil C. (1)
 CS (1) Dep. Respiratory Med., London Chest Hosp., London E2 9JX UK
 SO Lancet (North American Edition), (Oct. 3, 1998) Vol. 352, No. 9134, pp. 1109-1113.
 DT Article
 LA English
 L1 ANSWER 21 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:368117 BIOSIS
 DN PREV199800368117
 TI Clinical and immunologic effects of a PRIMAIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial.
 AU Yocum, David E. (1); Solinger, Alan M.; Tesser, John; Gluck, Oscar; Corneil, Michelle; O'Sullivan, Frank; Nordensson, Kathy; Dallaire, Brian; Shen, C. David; Lipani, John
 CS (1) Room 6409, 1501 N. Campbell, P.O. Box 245029, Tucson, AZ 85724 USA
 SO Journal of Rheumatology, (July, 1998) Vol. 25, No. 7, pp. 1257-1262.
 DT Article
 LA English
 L1 ANSWER 22 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:158088 BIOSIS
 DN PREV199800158088
 TI Treatment of rheumatoid arthritis with a Primateized anti-CD4 monoclonal antibody, SB-210396 (IDEC-CE9.1). Results of an open label extension study in patients responding to induction therapy.
 AU Tesser, John R. P. (1); Wiesenhutter, Craig; Levy, Robert; Schiff, Michael; Lipani, John; Solinger, Alan; Macdonald, Brian; Elliott, Michael; Singh, Krishan
 CS (1) Phoenix, AZ 85015 USA
 SO Arthritis & Rheumatism, (Sept., 1997) Vol. 40, No. 9 SUPPL., pp. S224.
 DT Meeting Info.: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals Washington, DC, USA November 8-12, 1997 Association of Rheumatology Health Professionals
 LA English
 L1 ANSWER 23 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:157892 BIOSIS
 DN PREV199800157892
 TI Treatment of rheumatoid arthritis with a Primateized anti-CD4 monoclonal antibody, SB-210396 (IDEC-CE9.1): Responsiveness correlates with duration of monoclonal antibody coating, CD4 receptor modulation and decrease in number of activated lymphocyte subpopulations.
 AU Truneh, Alem (1); Macdonald, Brian (1); Elliott, Michael (1); Singh, Krishan (1); Solinger, Alan
 CS (1) SmithKline Beecham, Collegeville, PA 19426 USA
 SO Arthritis & Rheumatism, (Sept., 1997) Vol. 40, No. 9 SUPPL., pp. S191.
 DT Meeting Info.: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals Washington, DC, USA November 8-12, 1997 Association of Rheumatology Health Professionals
 LA English
 L1 ANSWER 24 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:153757 BIOSIS
 DN PREV199800153757
 TI In vitro inhibitory effects of a PRIMAIZED anti-CD4 monoclonal antibody, SB210396 (IDEC CE9.1), on allergen specific T-cell proliferation and cytokine production in atopic asthmatics.
 AU Loh, L. C. (1); Kon, O. M. (1); Sihra, B. S. (1); Tili, S. J. (1); Barkans, J. (1); Compton, C. H.; Barnes, N. C.; Kay, A. B. (1)
 CS (1) Natl. Heart Lung Inst., SmithKline Beecham Pharmaceuticals, London UK
 SO Journal of Allergy and Clinical Immunology, (Jan., 1998) Vol. 101, No. 1 PART 2, pp. S11.
 DT Meeting Info.: 54th Annual Meeting of the American Academy of Allergy, Asthma and Immunology Washington, DC, USA March 13-18, 1998 American Academy of Allergy, Asthma, and Immunology

DT . ISSN: 0091-6749.
LA Conference

L1 ANSWER 25 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:153748 BIOSIS
DN PREV199800153748
TI In vivo effects of a PRIMATIZED anti-CD4 monoclonal antibody, SB210396 (IDEC CE9.1), on CD4+ T lymphocytes in chronic severe asthma.

AU Kon, O. M. (1); Sihra, B. S. (1); Barkans, J. (1); Compton, C. H.; Barnes, N. C.; Kay, A. B. (1)
CS (1) Natl. Heart Lung Inst., SmithKline Beecham Pharmaceuticals, London UK
SO Journal of Allergy and Clinical Immunology, (Jan., 1998) Vol. 101, No. 1 PART 2, pp. S9.
TI Meeting Info.: 54th Annual Meeting of the American Academy of Allergy, Asthma and Immunology Washington, DC, USA March 13-18, 1998 American Academy of Allergy, Asthma, and Immunology
ISSN: 0091-6749.

DT Conference
LA English

L1 ANSWER 26 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:105440 BIOSIS
DN PREV199800105440
TI Pharmacokinetics and pharmacodynamics of SB 210396 (IDEC CE9.1), a primatized anti-human CD4 monoclonal antibody, in patients with stable severe asthma.

AU Zia-Amirhosseini, P. (1); Citerone, D. R. (1); Davis, C. B. (1); Sihra, B. (1); Compton, C. H. (1); Kon, O. M.; Kay, A. B.; Barnes, N. C.
CS (1) SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406 USA
SO Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S509.

DT Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997
LA Conference
LA English

L1 ANSWER 27 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:104346 BIOSIS
DN PREV199800104346
TI Non-linear pharmacokinetics of SB 210396 (IDEC CE9.1), a primatized anti-human CD4 monoclonal antibody in transgenic mice bearing human CD4.

AU Davis, C. B.; Steiman, G. J.; Urbanski, J. J.
CS Drug Metabolism Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406 USA
SO Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S76.

DT Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997
LA Conference
LA English

L1 ANSWER 28 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:321016 BIOSIS
DN PREV199799611504
TI A primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a Mab (IDEC-CE9.1) to human CD4.

AU Anderson, Darrell; Chambers, Karen; Hanna, Nabil; Leonard, John; Reff, Mitchell; Newman, Roland (1); Baidoni, John; Dunleavy, Donna; Reddy, Manjula; Sweet, Raymond; Truneh, Alamegeed
CS (1) IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA 92121 USA
SO Clinical Immunology and Immunopathology, (1997) Vol. 84, No. 1, pp. 73-84.
TI Article
LA English

L1 ANSWER 29 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:514251 BIOSIS
DN PREV199699236607
TI Disposition of metabolically radiolabeled CE9.1-A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4.

AU Davis, Charles B. (1); Garver, Eric M.; Kwok, Deborah C.; Urbanski, James J.
CS (1) SmithKline Beecham Pharm., Drug Metabolism Pharm., P.O. Box 1539, Mail Code UW2730, 709 Swedeland Road, King of Prussia, PA 19406 USA
SO Drug Metabolism and Disposition, (1996) Vol. 24, No. 9, pp. 1032-1037.
TI Article
LA English

L1 ANSWER 30 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:501921 BIOSIS
DN PREV199699224277
TI Pharmacology and safety of anti-CD4 antibody IDEC-CE9.1 in HCD4 transgenic mice.

AU Bugelski, Peter (1); Griswold, Don; Badger, Allison; Rehm, Sabine; Truneh, Alamegeed; Herzyk, Danuta
CS (1) SmithKline Beecham Pharm., Philadelphia, PA USA
SO Arthritis & Rheumatism, (1996) Vol. 39, No. 9 SUPPL., pp. S247.

DT Meeting Info.: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals Orlando, Florida, USA October 18-22, 1996
LA Conference
LA English

L1 ANSWER 31 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:309276 BIOSIS
DN PREV199699031632
TI Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, non-depleting primatized anti-CD4 monoclonal antibody in rheumatoid arthritis (RA).

AU Solinger, A. (1); Paxton, H.; Mey, K.; Yocum, D.
CS (1) IDEC Pharmaceuticals, San Diego, CA 92121 USA
SO FASEB Journal, (1996) Vol. 10, No. 6, pp. A1314.

DT Meeting Info.: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists New Orleans, Louisiana, USA June 2-6, 1996
LA Conference
LA English

L1 ANSWER 32 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:309703 BIOSIS
DN PREV19959855003
TI Results of a multi-dose protocol 7002 using an immunomodulating, non-depleting PRIMATIZED anti-CD4 monoclonal antibody in rheumatoid arthritis (RA).

AU Kaine, Jeffrey (1); Solinger, Alan; Yocum, David; Lipani, John; Kias, Pam; Tesser, John; Miesenhunter, Craig; O'Sullivan, Frank; Shuman, Sherry; Rigny, William
 CS (1) Sarasota Arthritis Center, Sarasota, FL 34239 USA
 SO Arthritis & Rheumatism, (1995) Vol. 38, No. 9 SUPPL., pp. S185.
 Meeting Info.: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals San Francisco, California, USA October 21-26, 1995
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 33 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:287708 BIOSIS
 DN PREV199598302008
 TI Clinical and Immunopharmacologic effects of primatized-TM IDEC-CE9 .1, an anti-CD4 monoclonal antibody in a phase I trial in active rheumatoid arthritis.
 AU Yocum, D. E. (1); Solinger, A. M.; Lipani, J.; Tesser, J.; Gluck, O.; Sullivan, F. O.; Marrescu, M.; Cornett, M.; Wei, K.; Nordenson, K.
 CS (1) Univ. Arizona, Tucson, AZ USA
 SO Journal of Investigative Medicine, (1995) Vol. 43, No. SUPPL. 2, pp. 253A.
 Meeting Info.: Clinical Research Meeting San Diego, California, USA May 5-8, 1995
 DT Conference
 LA English
 L1 ANSWER 34 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:4701 BIOSIS
 DN PREV199598019001
 TI Clinical activity in an early phase I trial of primatized IDEC-CE9 .1 - an anti-CD4 monoclonal antibody in RA.
 AU Solinger, A. M. (1); Yocum, D. E.; Tesser, J.; Gluck, O.; O'Sullivan, F.; Henkel, C. (1); Cornett, M.; Lipani, J.
 CS (1) IDEC Pharm. Corp., San Diego, CA 92121 USA
 SO Arthritis & Rheumatism, (1994) Vol. 37, No. 9 SUPPL., pp. S337.
 Meeting Info.: 58th National Scientific Meeting of the American College of Rheumatology and the 29th National Scientific Meeting of the Association of Rheumatology Health Professionals Minneapolis, Minnesota, USA October 23-27, 1994
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 35 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:4695 BIOSIS
 DN PREV199598018995
 TI Immunomodulatory effect of primatized-TM IDEC-CE9.1 an Anti-CD4 monoclonal antibody, in RA.
 AU Yocum, D. E. (1); Nordenson, K. (1); Solinger, A. M.
 CS (1) Univ. Arizona, Tucson, AZ 85724 USA
 SO Arthritis & Rheumatism, (1994) Vol. 37, No. 9 SUPPL., pp. S336.
 Meeting Info.: 58th National Scientific Meeting of the American College of Rheumatology and the 29th National Scientific Meeting of the Association of Rheumatology Health Professionals Minneapolis, Minnesota, USA October 23-27, 1994
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:635297 CAPLUS
 DN 136:215315

TI The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma
 AU Kon, O. M.; Sihra, B. S.; Loh, L. C.; Barkans, J.; Compton, C. H.; Barnes, N. C.; Larche, M.; Kay, A. B.
 CS Dept. of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, London, SW3 6LY, UK
 SO European Respiratory Journal (2001), 18(1), 45-52
 CODEN: ERJOCJ; ISSN: 0903-1936
 PB European Respiratory Society
 DT Journal
 LA English
 RE.CNT 27
 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:477381 CAPLUS
 DN 131:138677
 TI Clenolimab SmithKline Beecham
 AU Norman, Peter
 CS Norman Consulting, Burnham, SL1 8JW, UK
 SO Current Opinion in Anti-Inflammatory and Immunomodulatory Investigational Drugs (1999), 1(2), 168-170
 CODEN: COAIFJ; ISSN: 1464-8474
 PB Current Drugs Ltd.
 DT Journal
 LA English
 RE.CNT 18
 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:130154 CAPLUS
 DN 130:346646
 TI Flow cytometry in the preclinical development of biopharmaceuticals
 AU Gossett, Kent A.; Narayanan, Padma K.; Williams, Donna M.; Gore, Elizabeth R.; Herzyk, Danuta J.; Hart, Timothy K.; Sellers, Teresa S
 CS SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
 SO Toxicologic Pathology (1999), 27(1), 32-37
 CODEN: TOPADD; ISSN: 0192-6233
 PB Society of Toxicologic Pathologists
 DT Journal
 LA English
 RE.CNT 8
 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:691752 CAPLUS
 DN 130:94193
 TI Randomized, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma
 AU Kon, Om M.; Sihra, Bhupinder S.; Compton, Christopher H.; Leonard, Thomas B.; Kay, A. Barry; Barnes, Neil C.
 CS London Chest Hospital, London, E2 9UX, UK
 SO Lancet (1998), 352(9134), 1109-1113
 CODEN: LANCAD; ISSN: 0140-6736
 PB Lancet Ltd.
 DT Journal
 LA English
 RE.CNT 24
 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:471014 CAPLUS
 DN 129:229418
 TI Clinical and immunologic effects of a primatized anti-CD4 monoclonal

antibody in active rheumatoid arthritis: results of a Phase I, single dose, dose escalating trial
 Yocum, David E.; Solinger, Alan M.; Tesser, John; Gluck, Oscar; Cornett, Michelle; O'Sullivan, Frank; Nordensson, Kathy; Dallaire, Brian; Shen, C. David; Lipani, John
 Department of Medicine, Arizona Health Sciences Center (AHSC), Tucson, AZ, 85724, USA
 CS Journal of Rheumatology (1998), 25(7), 1257-1262
 SO CODEN: JRMH09; ISSN: 0315-162X
 PB Journal of Rheumatology Publishing Co. Ltd.
 DT Journal
 LA English

ANSWER 41 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:426327 CAPLUS
 DN 129:156339
 TI Biological agents in rheumatoid arthritis: which ones could be used in combination?

LOrenz, Hanns-Martin; Kaiden, Joachim R.
 CS Department of Medicine III, Institute for Clinical Immunology and Rheumatology, University of Erlangen-Nuremberg, Erlangen, Germany
 SO CODEN: BIRH4; ISSN: 1173-8804
 PB Adis International Ltd.
 DT Journal: General Review
 LA English

ANSWER 42 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:417698 CAPLUS
 DN 129:153105
 TI Subcutaneous bioavailability of a PRIMATIZED IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4

DAvies, Charles B.; Bugelski, Peter J.
 CS Drug Metabolism Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
 SO Drug Delivery (1998), 5(12), 95-100
 PB CODEN: DDEL6; ISSN: 1071-7544
 DT Taylor & Francis
 LA English

ANSWER 43 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:123645 CAPLUS
 DN 128:191337
 TI The therapeutic potential of a primatized nondepleting anti-CD4 (IDEC-CE9.1) monoclonal antibody in rheumatoid arthritis

ASolinger, Alan M.; Truneh, Alesseged; Lipani, John A.; Newman, Roland A.
 CS IDEC Pharmaceuticals Corporation, San Diego, CA, USA
 SO Antibody Therapeutics (1997), 341-353. Editor(s): Harris, William J.; Adair, John R. Publisher: CRC, Boca Raton, Fla.
 CODEN: 65RLAP
 DT Conference: General Review
 LA English

ANSWER 44 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:423612 CAPLUS
 DN 127:120496
 TI A Primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo

ASolinger, Alan M.; Truneh, Alesseged; Lipani, John A.; Newman, Roland A.
 CS IDEC Pharmaceuticals Corporation, San Diego, CA, USA
 SO Antibody Therapeutics (1997), 341-353. Editor(s): Harris, William J.; Adair, John R. Publisher: CRC, Boca Raton, Fla.
 CODEN: 65RLAP
 DT Conference: General Review
 LA English

ANSWER 47 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:589160 CAPLUS
 DN 125:245208
 TI Disposition of metabolically radiolabeled CE9.1. - A maceque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4

SO Clinical Immunology and Immunopathology (1997), 84(1), 73-84
 CODEN: CLIMAT; ISSN: 0090-1229
 PB Academic
 DT Journal
 LA English

ANSWER 45 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:290112 CAPLUS
 DN 126:263167
 TI Recombinant anti-CD4 antibodies for human therapy

IN Hanna, Nabil; Newman, Roland A.; Reff, Mitchell E.
 PA Idex Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 154 pp.
 CODEN: PIXD2
 DT Patent
 LA English
 FAN. CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709351	A1	19970313	WO 1996-0514324	19960905
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, CG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 6136310	A	20001024	US 1995-323894	19950906
AU 9669162	A1	19970327	AU 1996-69162	19960905
EU 717674	B2	20000330		
EP 854885	A1	19980729	EP 1996-929936	19960905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9610404	A	19990706	BR 1996-10404	19960905
JP 11514216	T2	19991207	JP 1996-511411	19960905
NO 9800915	A	19980506	NO 1998-915	19980303
US 1995-523894	A	19950906		
US 1991-735064	B2	19910725		
US 1992-856281	B2	19920323		
US 1992-912292	B1	19920710		
US 1995-379072	A2	19950125		
US 1995-476237	A2	19950607		
WO 1996-US14324	W	19960905		

ANSWER 46 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:46760 CAPLUS
 DN 126:142904
 TI The use of CE9.1, a primatized monoclonal anti-CD4, in the treatment of rheumatoid arthritis

AYocum, David E.; Solinger, Alan M.; Lipani, John A.
 CS College Medicine, University Arizona, Tucson, AZ, USA
 SO Novel Therapeutic Agents for the Treatment of Autoimmune Diseases (1997), 65-74. Editor(s): Strand, Vibeke; Scott, David L.; Simon, Lee S. Publisher: Dekker, New York, N. Y.
 CODEN: 63VZAS
 DT Conference: General Review
 LA English

ANSWER 47 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:589160 CAPLUS
 DN 125:245208
 TI Disposition of metabolically radiolabeled CE9.1. - A maceque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4

AU Davis, Charles B.; Garver, Eric M.; Kwok, Deborah C.; Urbanaki, James J.
 CS Drug Metab. Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King
 SO Prussia, Pa, 19406, USA
 DT Drug Metab. Dispos. (1996), 24(9), 1032-1037
 LA CODEN: DMSAI; ISSN: 0090-9556
 DT Journal
 LA English
 L1 ANSWER 48 OF 63 USPTFULL
 AN 2002:144299 USPTFULL
 TI Conjugates of dithiocarbamates with pharmacologically active agents and
 IN uses therefor
 PA Lai, Ching-San, Encinitas, CA, United States
 PA Wang, Tingmin, San Marcos, CA, United States
 PI Medinex, Inc., San Diego, CA, United States (U.S. corporation)
 AI US 6407135 B1 20020618
 RLI US 1999-453608 19991203 (9)
 DT Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998
 FS Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now
 IN patented, Pat. No. US 5916910
 DT Utility
 FS GRANTED
 LN CNT 2157
 INCL INCLM: 514/423.000
 NCL INCLS: 514/002.000; 514/514.000; 530/402.000; 548/565.000; 548/573.000
 NCLM: 514/423.000
 IC NCLS: 514/002.000; 514/514.000; 530/402.000; 548/565.000; 548/573.000
 [7]
 ICM: C07D207-04
 ICS: C07D207-30; A61K038-00; A61K031-27; A61K031-40
 EXF 530/402; 530/300; 530/356; 514/8-25; 514/2; 514/423; 514/514; 548/565;
 548/573
 L1 ANSWER 49 OF 63 USPTFULL
 AN 2002:85531 USPTFULL
 TI POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE
 IN THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
 PA LAI, CHING-SAN, ENCINITAS, CA, UNITED STATES
 PI US 2002045573 A1 20020418
 AI US 1999-409645 A1 19991001 (9)
 RLI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997,
 ABANDONED
 PRAI US 1996-25867P 19960910 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1763
 INCL INCLM: 514/006.000
 NCL INCLS: 514/044.000; 514/054.000; 514/476.000; 514/483.000; 530/403.000;
 514/404.000; 514/405.000; 536/022.100; 536/123.100
 NCLM: 514/006.000
 IC NCLS: 514/044.000; 514/054.000; 514/476.000; 514/483.000; 530/403.000;
 514/404.000; 514/405.000; 536/022.100; 536/123.100
 [7]
 ICM: A61K038-16
 ICS: A61K031-415; C07H021-00; A61K031-715; A01N043-04; A61K031-70;
 C07H001-00; C08H001-00; C07K017-00; A01N043-56; A61K031-27; A01N047-10
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 50 OF 63 USPTFULL
 AN 2002:47987 USPTFULL
 TI Treatment of B cell malignancies using combination of B cell depleting
 IN antibody and immune modulating antibody related applications
 PA Hanne, Nabil, Rancho Santa Fe, CA, UNITED STATES
 PA Hartharan, Kandassamy, San Diego, CA, UNITED STATES

PI US 2002028178 A1 20020307
 AI US 2001-855717 A1 20010516 (9)
 PRAI US 2000-217706P 20000712 (60)
 DT Utility
 FS APPLICATION
 LN CNT 3047
 INCL INCLM: 424/001.490
 NCL INCLS: 424/143.100
 NCLM: 424/001.490
 IC NCLS: 424/143.100
 [7]
 ICM: A61K039-395
 ICS: A61K051-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 51 OF 63 USPTFULL
 AN 2002:12028 USPTFULL
 TI Treatment of cell malignancies using combination of B cell depleting
 IN antibody and immune modulating antibody related applications
 PA Hanne, Nabil, Rancho Santa Fe, CA, UNITED STATES
 PA Hartharan, Kandassamy, San Diego, CA, UNITED STATES
 PI IDEC Pharmaceuticals Corporation (U.S. corporation)
 AI US 2002006404 A1 20020117
 RLI US 2001-772938 A1 20010131 (9)
 DT Continuation-in-part of Ser. No. US 1999-435992, filed on 8 Nov 1999,
 PENDING
 DT Utility
 FS APPLICATION
 LN CNT 2147
 INCL INCLM: 424/142.100
 NCL INCLS: 424/155.100
 NCLM: 424/142.100
 IC NCLS: 424/155.100
 [7]
 ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 52 OF 63 USPTFULL
 AN 2001:237946 USPTFULL
 TI Method of treating immune cell mediated systemic diseases
 IN Bugelski, Peter John, Drexel Hill, PA, United States
 PA Davis, Charles Baldwin, Devon, PA, United States
 PA MacDonald, Brian Richard, Valley Forge, PA, United States
 PI SmithKline Beecham Corporation (U.S. corporation)
 AI US 2001056066 A1 20011227
 RLI US 2001-905836 A1 20010713 (9)
 DT Continuation of Ser. No. US 1999-230119, filed on 26 May 1999, ABANDONED
 A 371 of International Ser. No. WO 1997-US12600, filed on 25 Jul 1997,
 UNKNOWN
 PRAI US 1996-22472P 19960726 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1105
 INCL INCLM: 514/008.000
 NCL INCLS: 424/131.100
 NCLM: 514/008.000
 IC NCLS: 424/131.100
 [7]
 ICM: A61K038-16
 ICS: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 53 OF 63 USPTFULL
 AN 2001:202682 USPTFULL

TI Therapeutic methods employing disulfide derivatives of dithiocarbonates
 IN Lai, Ching-San, Encinitas, CA, United States
 PA Vassiliev, Vassil, San Diego, CA, United States
 PI US 6316502 B1 20011113
 AI US 2000-565666 Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented,
 RLI Pat. No. US 6093743
 DT Utility
 FS GRANTED
 INCL LN.CNT 2591
 INCLM: 514/599.000
 INCL: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
 NCL 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
 NCLM: 514/599.000
 NCIS: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
 IC 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
 [7]
 ICM: A01N037-18
 EXF 514/599; 514/707; 514/825; 514/838; 514/851; 514/861; 514/863; 514/885;
 514/866; 514/903; 514/912; 514/925
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 54 OF 63 USPTAFULL
 AN 2001:188209 USPTAFULL
 TI Vaccine and immunotherapy for solid nonlymphoid tumor and related immune
 IN dysregulation
 PI Barbera-Guilliem, Emilio, Powell, OH, United States
 AI US 2001033839 AI 20011025
 RLI US 2001-835759 AI 20010416 (9)
 DT Continuation-in-part of Ser. No. US 1999-411116, filed on 4 Oct 1999,
 UNKNOWN
 FS Utility
 INCL LN.CNT 2272
 INCLM: 424/130.100
 INCL: 424/184.100
 NCL 424/130.100
 NCIS: 424/184.100
 IC 424/184.100
 ICM: A61K039-395
 ICS: A61K039-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 55 OF 63 USPTAFULL
 AN 2001:173390 USPTAFULL
 TI Transgenic non-human animals for producing heterologous antibodies
 IN Lomberg, Nils, Redwood City, CA, United States
 PA Kay, Robert M., San Francisco, CA, United States
 PI GenPharm International, Palo Alto, CA, United States (U.S. corporation)
 AI US 6300129 B1 20011009
 RLI US 1996-758417 19961202 (8)
 DT Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996
 FS now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US
 INCL LN.CNT 2173
 INCLM: 514/599.000
 INCL: 514/706.000; 514/707.000
 NCL 514/599.000
 NCIS: 514/706.000; 514/707.000
 [7]

1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016
 Continuation-in-part of Ser. No. US 1992-590860, filed on 16 Dec 1992,
 now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US
 1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of
 Ser. No. US 1992-833408, filed on 18 Mar 1992, now patented, Pat. No. US
 5789650 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec
 1991, now patented, Pat. No. US 5569825 Continuation-in-part of Ser. No.
 US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part
 of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
 DT Utility
 FS GRANTED
 INCL LN.CNT 10030
 INCLM: 435/326.000
 INCL: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
 NCL 800/018.000
 NCLM: 435/326.000
 NCIS: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
 IC 800/018.000
 [7]
 ICM: C12N015-86
 EXF 800/3; 800/6; 800/18; 435/326; 435/346; 435/354; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 56 OF 63 USPTAFULL
 AN 2001:144906 USPTAFULL
 TI Treatment of B cell malignancies using anti-CD40L antibodies in
 IN combination with anti-CD20 antibodies and/or chemotherapeutics and
 radiotherapy
 PI Hanna, Nabill, Rancho Santa Fe, CA, United States
 PA Hartharan, Kandassamy, San Diego, CA, United States
 PI IDC Pharmaceuticals Corporation (U.S. corporation)
 AI US 2001018041 AI 20010830
 RLI US 2001-834933 AI 20010416 (9)
 DT Division of Ser. No. US 1999-435922, filed on 8 Nov 1999, PENDING
 FS Utility
 INCL LN.CNT 1728
 INCLM: 424/001.490
 INCL: 424/181.100
 NCL 424/001.490
 NCIS: 424/181.100
 IC 424/181.100
 ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 57 OF 63 USPTAFULL
 AN 2001:131342 USPTAFULL
 TI Conjugates of dithiocarbamate disulfides with pharmacologically active
 IN agents and uses therefor
 PA Lai, Ching-San, Encinitas, CA, United States
 PI Vassiliev, Vassil P., San Diego, CA, United States
 AI Medinex, Inc., San Marcos, CA, United States
 RLI US 6274627 B1 20010814
 DT Continuation-in-part of Ser. No. US 1999-416619 19991012 (9)
 FS Utility
 INCL LN.CNT 2173
 INCLM: 514/599.000
 INCL: 514/706.000; 514/707.000
 NCL 514/599.000
 NCIS: 514/706.000; 514/707.000
 [7]

ICM: A61K031-16
ICS: A61K031-095; A61K031-105
514/599; 514/706; 514/707
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 58 OF 63 USPTFULL
AN 2001:102968 USPTFULL
TI High affinity human antibodies and human antibodies against digoxin
IN Lombey, Nils, Woodside, CA, United States
PA Key, Robert M., San Francisco, CA, United States
PI Genharm International, San Jose, CA, United States (U.S. corporation)
AI US 6255458 B1 20010703
R1 US 1998-42353 19980313 (9)

Continuation-in-part of Ser. No. US 1996-758417, filed on 2 Dec 1996
Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996
Continuation-in-part of Ser. No. US 1995-544404, filed on 10 Oct 1995,
now patented, Pat. No. US 5710429 Continuation-in-part of Ser. No. US
1994-332322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 5814318 Continuation-in-part of Ser. No. US
1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016
Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992,
now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US
1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of
Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US
5788650 Continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb
1992, now patented, Pat. No. US 5633425 Continuation-in-part of Ser. No.
US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5568825
Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990,
now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on
29 Aug 1990, now abandoned
DT Utility
FS GRANTED
IN.CNT 10059
INCL INCLM: 530/388.150
INCLM: 530/388.900; 435/326.000
NCL NCIM: 530/388.150
NCLM: 530/388.150
IC NCLS: 435/326.000; 530/388.900
ICM: C07K016-00
EXF 424/175.1; 435/326; 435/346; 435/345; 530/388.9; 530/388.15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 59 OF 63 USPTFULL
AN 2000:141878 USPTFULL
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabil, Olivenhain, CA, United States
PA Newman, Roland Anthony, San Diego, CA, United States
PI Reff, Mitchell Elliot, San Diego, CA, United States
R1 IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
AI US 6136310 20001024
AI US 1995-523894 19950906 (8)
TI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,
now patented, Pat. No. US 5736096 which is a continuation-in-part of
Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US
5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10
Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, now abandoned which is a

continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,
now abandoned
DT Utility
FS Granted
IN.CNT 3398
INCL INCLM: 424/154.100
INCLM: 530/387.300; 424/133.100; 424/141.100
NCL NCIM: 424/154.100
NCLM: 424/133.100; 424/141.100; 530/387.300
IC ICM: A61K039-395
ICS: C12P021-08
EXF 530/387.3; 424/133.1; 424/141.1; 424/154.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 60 OF 63 USPTFULL
AN 2000:95042 USPTFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates
and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
PA Vassiliev, Vassil, San Diego, CA, United States
PI Vassilov, Vassil, San Diego, CA, United States (U.S. corporation)
AI US 6093743 20000725
DT US 1998-103639 19980623 (9)
DT Utility
FS Granted
IN.CNT 2691
INCL INCLM: 514/599.000
INCLM: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
514/866.000; 514/909.000; 514/912.000
NCL NCIM: 514/599.000
NCLM: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
514/866.000; 514/909.000; 514/912.000
IC (7)
ICM: A61K031-16
EXF ICS: A61K031-095; A61K031-105
514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 61 OF 63 USPTFULL
AN 2000:1981 USPTFULL
TI Gamma-1 anti-human CD23 monoclonal antibodies
IN Reff, Mitchell E., San Diego, CA, United States
PA Klotzer, William S., Carlsbad, CA, United States
PI Nakamura, Takehiko, Higashiyamato, Japan
R1 IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
AI Seikagaku Corporation, Japan (non-U.S. corporation)
AI US 6011138 20000104
DT US 1997-803085 19970220 (8)
DT Utility
FS Granted
IN.CNT 2519
INCL INCLM: 530/388.220
INCLM: 530/387.300; 530/388.200; 530/388.150; 530/388.730; 530/389.600;
530/387.900; 424/133.100; 424/139.100; 424/142.100; 424/144.100;
424/153.100; 424/173.100; 424/172.100; 435/007.240; 435/069.600;
435/069.700; 435/070.210; 435/328.000; 435/331.000; 435/332.000;
435/334.000; 435/343.100
NCL NCIM: 530/388.220
NCLM: 424/133.100; 424/139.100; 424/142.100; 424/144.100; 424/153.100;
424/172.100; 424/173.100; 435/007.240; 435/069.600; 435/069.700;
435/070.210; 435/328.000; 435/331.000; 435/332.000; 435/334.000;

435/343.100; 530/387.300; 530/387.900; 530/388.150; 530/388.200;
530/388.730; 530/389.600

IC [6]
ICM: A61K039-395
ICS: C12N005-12; C12N005-22; C07K016-28
EXF 530/387.14; 530/387.3; 530/388.22; 530/388.2; 530/389.6; 424/643.1;
424/133.1; 424/143.1; 424/139.1; 424/142.1; 424/144.1; 424/153.1;
435/69.6; 435/69.7; 435/328; 435/334; 435/172.3; 435/7.24; 435/70.21;
435/331; 435/333.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 62 OF 63 USPATFULL
AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and
uses therefore
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinex, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
LN.CNT 1842
INCL INCLM: 514/423.000
NCL INCLM: 514/514.000; 548/564.000; 548/573.000; 558/235.000
NCLM: 514/423.000
NCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
IC [6]
ICM: C07D207-04
EXF ICS: C07D207-30; A61K031-27; A61K031-40
514/514; 514/423; 548/565; 548/573; 558/235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 63 OF 63 USPATFULL
AN 1998:57523 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabli, Olivenhain, CA, United States
PA Raab, Ronald W., San Diego, CA, United States
IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 5756096 19980526
AI US 1995-476237 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995,
now patented, Pat. No. US 5658570 which is a continuation of Ser. No. US
1992-912292, filed on 10 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility
FS Granted
LN.CNT 1919
INCL INCLM: 424/154.100
NCL INCLM: 424/133.100; 424/141.100; 530/387.100
NCLM: 424/154.100
NCLS: 424/133.100; 424/141.100; 530/387.100
IC [6]
ICM: A61K039-395
EXF 424/133.1; 424/141.1; 424/154.1; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
12:18:32 ON 25 JUN 2002

L1 63 S CE9.1
L2 0 S LI NOT PY=>1991
L3 39370 S CHIMER? AND ANTIBOD?
L4 5562 S PRIMATE AND HUMAN AND L3
L5 1188 S CD4 AND L4
L6 4708 S L3 AND CD4
L7 121 S L6 NOT PY=>1991
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> d 18 1-62

L8 ANSWER 1 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN 1990:629546 CAPLUS
DN 113:229546
TI Chimeric and mosaic antibodies to Leu 3a antigen
IN Hinton, Robert; Ol, Vernon T.
PA Becton, Dickinson and Co., USA
SO Eur. Pat. Appl., 12 pp.
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 365209	A2	19900425	EP 1989-310415	19891011
EP 365209	A3	19900725		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02238863	A2	19900921	JP 1989-270152	19891017
PRAI US 1968-260558		19881017		

L8 ANSWER 2 OF 62 USPATFULL
AN 90:67552 USPATFULL
TI Genes and their encoded proteins which regulate gene expression of the
interleukin-2 receptor and of human lymphotropic retroviruses
IN Cantor, Harvey I., Wellesley, MA, United States
Patarca, Roberto, Brookline, MA, United States
PA Dana-Farber Cancer Institute, Boston, MA, United States (U.S.
corporation)
PI US 4952499 19900828
AI US 1988-154758 19880211 (7)
DT Utility
FS Granted
LN.CNT 1340
INCL INCLM: 435/172.300
NCL INCLM: 435/091.000; 435/172.100; 435/320.000; 435/252.330; 435/240.200;
435/069.100; 435/320.000; 435/252.330; 435/240.200; 435/069.100
NCLM: 435/069.100
NCLS: 435/252.330; 435/320.100; 435/358.000; 435/372.300; 435/455.000;
536/023.520; 536/023.720; 536/024.100
IC [5]
ICM: C12P021-00
EXF ICS: C12P021-02; C12P019-34; C12N015-00
435/60; 435/70; 435/91; 435/172.1; 435/172.3; 435/320; 530/350; 536/27;
935/18; 935/32; 935/36; 935/58; 935/60; 935/70; 935/71
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 62 USPATFULL
AN 90:38221 USPATFULL
TI Detection and treatment of infectious and inflammatory lesions
IN Hansen, Hans J., Westfield, NJ, United States
Goldenberg, Milton D., Short Hills, NJ, United States

PA Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
 PI US 4925648 19900515
 A1 US 1988-226180 19880729 (7)
 DT Utility
 FS Granted
 LN.CNT 991
 INCL INCLM: 424/001.100
 INCLS: 424/009.000; 424/085.800; 424/085.910; 530/389.000; 530/402.000;
 NCL NCLM: 424/001.530
 NCLS: 252/001.000; 424/009.340; 424/136.100; 424/153.100; 424/154.100;
 424/178.100; 530/388.700; 530/388.730; 530/388.750; 530/389.600;
 530/391.300; 530/402.000; 530/866.000
 IC (5)
 ICM: A61K049-02
 ICS: A61K049-00; A61K039-395
 424/1.1; 424/9; 424/85.91; 424/85.8; 530/387; 530/388; 530/389; 530/402;
 252/1
 EXF
 L8 ANSWER 4 OF 62 MEDLINE DUPLICATE 1
 AN 91012791
 DN 91012791 PubMed ID: 1976822
 TI Lymphocyte subset alterations and viral determinants of immunodeficiency
 AU disease induction by the feline leukemia virus FeLV-FAIDS.
 CS Quackenbush S L; Donahue P R; Dean G A; Myles M H; Ackley C D; Cooper M D;
 Mullins J I; Hoover E A
 NC Department of Pathology, Colorado State University, Fort Collins 80523.
 CA-43216 (NCI)
 SO JOURNAL OF VIROLOGY, (1990 Nov) 64 (11) 5465-74.
 CY Journal code: 0113724. ISSN: 0022-538X.
 DT United States
 LA English
 FS Priority Journals; AIDS
 EM 199011
 ED Entered STN: 19910117
 Last Updated on STN: 19950206
 Entered Medline: 19901115
 L8 ANSWER 5 OF 62 MEDLINE DUPLICATE 2
 AN 90311331
 DN 90311331 PubMed ID: 2142306
 TI Human immunodeficiency virus infection is efficiently mediated by a
 AU glycolipid-anchored form of CD4
 CS Diamond D C; Finberg R; Chaudhuri S; Sleckman B P; Burakoff S J
 NC Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
 02115.
 IFC3 A107843-01 (NIAID)
 IT32 GM07753-08 (NIGMS)
 A117258-08 (NIAID)
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
 AMERICA, (1990 Jul) 87 (13) 5001-5
 CY Journal code: 7505876. ISSN: 0027-8424.
 DT United States
 LA English
 FS Priority Journals; AIDS
 EM 199008
 ED Entered STN: 19900921
 Last Updated on STN: 19970203
 Entered Medline: 19900815
 L8 ANSWER 6 OF 62 MEDLINE DUPLICATE 3

AN 90278062 MEDLINE
 DN 90278062 PubMed ID: 1972161
 TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A
 study using a set of chimeric anti-CD4
 antibodies
 AU Alters S E; Sakai K; Steinman L; Oi V T
 CS Program in Cancer Biology, Stanford University School of Medicine, CA
 94305.
 NC CA-39302 (NCI)
 SO ROINS18235 (NINDS)
 JOURNAL OF IMMUNOLOGY, (1990 Jun 15) 144 (12) 4587-92.
 CY Journal code: 2985117R. ISSN: 0022-1767.
 DT United States
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199007
 ED Entered STN: 19900824
 Last Updated on STN: 20000303
 Entered Medline: 19900718
 L8 ANSWER 7 OF 62 MEDLINE DUPLICATE 4
 AN 91060926
 DN 91060926 PubMed ID: 2147194
 TI Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results
 AU in specific deletion of antigen-activated T cell clones.
 CS Baatos M G; Pankewycz O; Rubin-Kelley V E; Murphy J R; Strom T B
 Department of Medicine, Beth Israel Hospital, Harvard Medical School,
 Boston, MA 02115.
 SO JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.
 CY Journal code: 2985117R. ISSN: 0022-1767.
 DT United States
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199101
 ED Entered STN: 19910222
 Last Updated on STN: 19910222
 Entered Medline: 19910107
 L8 ANSWER 8 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:346757 BIOSIS
 DN BR39:42018
 TI CONSTRUCTION EXPRESSION AND FUNCTIONAL ANALYSIS OF A CHIMERIC
 AU ALPHA-CD4 CHIMERIC OKT4 ANTIBODY.
 CS COLLINS A; PUTITO V; GARRISON L; TRINKER S; VARGA S; OLSEN W; GHOBRIAL I;
 MCRAHON M; SCHNELL J; ET AL
 R.W. JOHNSON PHARM. RES. INST., RARITAN, N.J., USA.
 SO JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR
 BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS,
 LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J. (1990) 4
 (7), A2085.
 DT CODEN: FAJDEE. ISSN: 0892-6638.
 FS Conference
 LA BR: OLD
 English
 L8 ANSWER 9 OF 62 MEDLINE
 AN 91006312
 DN 91006312 PubMed ID: 2209702
 TI The requirement of intrathymic mixed chimerism and clonal
 AU deletion for a long-lasting skin allograft tolerance in
 cyclophosphamide-induced tolerance.
 Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Nomoto K

L8 ANSWER 16 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:111619 BIOSIS
 DN BAB9:61110
 TI NATURAL HISTORY OF MIXED CHIMERISM AFTER BONE MARROW
 TRANSPLANTATION WITH CD6-DEPLETED ALLOGENEIC MARROW A STABLE EQUILIBRIUM.
 AU ROY D C; TANTRAHAH R; MURRAY C; DEAR K; GORCONE B; ANDERSON K C; FREEDMAN
 A S; NADLER L M; RITZ J
 CS DANA-FARBER CANCER INST., 44 BINNEY ST., BOSTON, MASS. 02115.
 SO BLOOD, (1990) 75 (1), 297-304.
 CODEN: BLOOAW. ISSN: 0006-4971.
 FS BA; OLD
 LA English
 L8 ANSWER 17 OF 62 MEDLINE
 AN 90105697 MEDLINE
 DN 90105697 PubMed ID: 1967216
 TI Natural history of mixed chimerism after bone marrow
 transplantation with CD6-depleted allogeneic marrow: a stable equilibrium.
 AU Roy D C; Tantravahi R; Murray C; Dear K; Gorgone B; Anderson K C; Freedman
 A S; Nadler L M; Ritz J
 CS Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA
 02115.
 NC N01-A1-62531
 SO BLOOD, (1990 Jan 1) 75 (1) 296-304.
 CY Journal code: 7603509. ISSN: 0006-4971.
 DT English
 LA Journal; Article; (JOURNAL ARTICLE)
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199002
 ED Entered STN: 19900328
 Last Updated on STN: 19950206
 Entered Medline: 19900209
 L8 ANSWER 18 OF 62 MEDLINE
 AN 90227722 MEDLINE
 DN 90227722 PubMed ID: 1970279
 TI Natural suppressor cells in spleens of irradiated, bone
 marrow-reconstituted mice and normal bone marrow: lack of Sca-1 expression
 and enrichment by depletion of Mac1-positive cells.
 AU Sykes M; Sharabi Y; Sachs D H
 CS Immunology Branch, National Cancer Institute, National Institutes of
 Health, Bethesda, Maryland 20892.
 SO CELLULAR IMMUNOLOGY, (1990 May) 127 (2) 260-74.
 CY Journal code: 1246405. ISSN: 0008-8749.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199005
 ED Entered STN: 19900706
 Last Updated on STN: 19950206
 Entered Medline: 19900531
 L8 ANSWER 19 OF 62 MEDLINE
 AN 91130709 MEDLINE
 DN 91130709 PubMed ID: 1980901
 TI SIVMM infection of macaque and mangabey monkeys: correlation between in
 vivo and in vitro properties of different isolates.
 AU Fultz P N; Anderson D C; McClure H M; Demhurst S; Mullins J I
 CS Yerkes Regional Primate Research Center, Atlanta, GA.
 CS AT-85007 (NIAID)
 CA-01058 (NCI)
 RR-00165 (NCRR)

SO DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1990) 72 253-8.
 CY Journal code: 0427140. ISSN: 0301-5149.
 DT Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199103
 ED Entered STN: 19910405
 Last Updated on STN: 19970203
 Entered Medline: 19910320
 L8 ANSWER 20 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1991:130377 BIOSIS
 DN BR40:62062
 TI IN-VITRO AND IN-VIVO CHARACTERISTICS OF A CHIMERIC HUMAN-MOUSE
 MONOCLONAL CD4 ANTIBODY.
 AU REITER C; FEUCHT H; RIEBER E P; DALESANDRO M; GRAYEB J; DADDOONA P;
 RIETHMUELLER G
 CS INST. IMMUNOL., UNIV. MUNICH, 8000 MUENCHEN, FRG.
 SO XXI MEETING OF THE SOCIETY OF IMMUNOLOGY, AACHEN, GERMANY, SEPTEMBER
 12-16, 1990. IMMUNOBIOLOGY, (1990) 181 (2-3), 219-220.
 DT Conference
 FS BR; OLD
 LA English
 L8 ANSWER 21 OF 62 MEDLINE
 AN 90293680 MEDLINE
 DN 90293680 PubMed ID: 1977228
 TI Specific tolerance induction across a xenogeneic barrier: production of
 mixed rat/mouse lymphohematopoietic chimeras using a nonlethal
 preoperative regimen.
 AU Sharabi Y; Aksentijevich I; Sundt T M 3rd; Sachs D H; Sykes M
 CS Transplantation Biology Section, National Cancer Institute, National
 Institutes of Health, Bethesda, Maryland 20892.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1990 Jul 1) 172 (1) 195-202.
 CY Journal code: 2985109. ISSN: 0022-1007.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 ED Entered STN: 19900907
 Last Updated on STN: 19950206
 Entered Medline: 19900801
 L8 ANSWER 22 OF 62 MEDLINE
 AN 90324622 MEDLINE
 DN 90324622 PubMed ID: 2197330
 TI Determination of mixed chimerism by a simple flow cytometry
 method.
 AU Leenarts P L; Vandeputte M; Waer M
 CS Division of Nephrology, University of Leuven, Belgium.
 SO JOURNAL OF IMMUNOLOGICAL METHODS, (1990 Jul 3) 130 (2) 163-9.
 CY Journal code: 1303440. ISSN: 0022-1759.
 DT Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 ED Entered STN: 19901012
 Last Updated on STN: 19901012
 Entered Medline: 19900824

L8 ANSWER 23 OF 62 MEDLINE
 AN 90293680 MEDLINE
 DN 90293680 PubMed ID: 1977228
 TI Specific tolerance induction across a xenogeneic barrier: production of
 mixed rat/mouse lymphohematopoietic chimeras using a nonlethal
 preoperative regimen.
 AU Sharabi Y; Aksentijevich I; Sundt T M 3rd; Sachs D H; Sykes M
 CS Transplantation Biology Section, National Cancer Institute, National
 Institutes of Health, Bethesda, Maryland 20892.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1990 Jul 1) 172 (1) 195-202.
 CY Journal code: 2985109. ISSN: 0022-1007.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 ED Entered STN: 19900907
 Last Updated on STN: 19950206
 Entered Medline: 19900801
 L8 ANSWER 24 OF 62 MEDLINE
 AN 90324622 MEDLINE
 DN 90324622 PubMed ID: 2197330
 TI Determination of mixed chimerism by a simple flow cytometry
 method.
 AU Leenarts P L; Vandeputte M; Waer M
 CS Division of Nephrology, University of Leuven, Belgium.
 SO JOURNAL OF IMMUNOLOGICAL METHODS, (1990 Jul 3) 130 (2) 163-9.
 CY Journal code: 1303440. ISSN: 0022-1759.
 DT Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 ED Entered STN: 19901012
 Last Updated on STN: 19901012
 Entered Medline: 19900824

L8 ANSWER 23 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:48737 BIOSIS
DN BR39:106758
TI A PHASE I CLINICAL TRIAL WITH CHIMERIC ANTI-CD4
AU MONOCLONAL ANTIBODY IN PATIENTS WITH MYCOSIS FUNGOIDES.
CS KNOX S J; HOGKINSON S; BELL B; BROWN S; WOOD G; HOPE R; ABEL A A;
STANFORD UNIV. SCH. MED.; STANFORD, CALIF.
SO SYMPOSIUM ON CELLULAR IMMUNITY AND THE IMMUNOTHERAPY OF CANCER HELD AT THE
19TH ANNUAL UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIUM ON
MOLECULAR AND CELLULAR BIOLOGY, PARK CITY, UTAH, USA, JANUARY 27-FEBRUARY
3, 1990. J CELL BIOCHEM SUPPL. (1990) 0 (14 PART B), 108.
CODEN: JCBSD7.
DT Conference
FS BR; OLD
LA English

L8 ANSWER 24 OF 62 MEDLINE
AN 91207985 MEDLINE
DN 91207985 Pubmed ID: 1708275
TI Cytotoxic T lymphocyte recognition of the H-2-erbB hybrid gene product
AU lacking the complete H-2 domain structure.
CS Ding L; Isobe K; Iwamoto T; Yoshida T; Nagase F; Kawashima K; Nakashima I
Department of Immunology, Nagoya University School of Medicine, Japan.
SO INTERNATIONAL IMMUNOLOGY, (1990) 2 (1) 91-7.
JOURNAL CODE: 8916182. ISSN: 0953-8178.
CY ENGLAND: United Kingdom
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199105
ED Entered STN: 19910616
Last Updated on STN: 19970203
Entered Medline: 19910529

L8 ANSWER 25 OF 62 MEDLINE
AN 91008471 MEDLINE
DN 91008471 Pubmed ID: 2211189
TI Cytotoxic and proliferative T-cell clones with antitumor reactivity from a
AU patient transplanted for severe combined immunodeficiency disease.
CS Keever C A; Flomenberg N; Gazzola M V; Fekle K; Yang S Y; Small T N;
Collins N H; O'Reilly R J
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer
Center, New York, New York.
NC CA-08748 (NCI)
CA-33050 (NCI)
CT5T32CA09512-02 (DCRT)
SO HUMAN IMMUNOLOGY, (1990 Sep) 29 (1) 42-55.
JOURNAL CODE: 8010936. ISSN: 0198-8859.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199011
ED Entered STN: 19910117
Last Updated on STN: 19960129
Entered Medline: 19901116

L8 ANSWER 26 OF 62 MEDLINE
AN 91185531 MEDLINE
DN 91185531 Pubmed ID: 2081787
TI The use of monoclonal antibodies for treatment of autoimmune
AU disease.
Steinman L

DUPLICATE 13

DUPLICATE 14

DUPLICATE 15

CS Department of Neurology and Genetics, Stanford University, California
94305.
SO JOURNAL OF CLINICAL IMMUNOLOGY, (1990 Nov) 10 (6 Suppl) 30S-38S;
discussion 38S-39S. Ref: 21
JOURNAL CODE: 8102137. ISSN: 0271-9142.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA General Review; (REVIEW)
FS (REVIEW, TUTORIAL)
EM English
ED Entered STN: 19910526
Last Updated on STN: 20000303
Entered Medline: 19910509

L8 ANSWER 27 OF 62 MEDLINE
AN 90226048 MEDLINE
DN 90226048 Pubmed ID: 2109590
TI A CD 4: Immunoglobulin fusion protein with antiviral effects against HIV.
AU Gregersen J P; Mehdi S; Gelderblom H; Zeltwiesl G
Research Laboratories, Behringwerke AG, Marburg, Federal Republic of
Germany.
SO ARCHIVES OF VIROLOGY, (1990) 111 (1-2) 29-43.
JOURNAL CODE: 7506870. ISSN: 0304-8608.
CY Austria
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals: AIDS
EM 199005
ED Entered STN: 19900622
Last Updated on STN: 19970203
Entered Medline: 19900521

L8 ANSWER 28 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN 1990:137060 CAPLUS
DN 112:137060
TI A comparison of rat and rat-mouse chimeric anti-murine
AU CD4 antibodies for use in immunotherapy
CS Alters, Susan Ellen
Stanford Univ., Stanford, CA, USA
SO (1989) 98 pp. Avail.: Univ. Microfilms Int., Order No. DA8925820
From: Diss. Abstr. Int. B 1990, 50(7), 2830
DT Dissertation
LA English

L8 ANSWER 29 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN 1990:156563 CAPLUS
DN 112:156563
TI Improvements relating to the production of monoclonal antibodies
AU using chimeric proteins
CS Bodmer, Walter Fred; Bodmer, Julia Gwynne; Maddox, Jill Faye; Reynolds,
Gary
PA Imperial Cancer Research Technology Ltd., UK
SO PCT Int. Appl., 30 pp.
DT Patent
LA CODEN: PIXXD2
EM English
ED FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
W: JP, US AI 19890601 WO 1988-GB1013 19881118
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

PRAI GB 1987-27030 19871118

L8 ANSWER 30 OF 62 MEDLINE
AN 89315834
DN 89315834 Pubmed ID: 2501790
TI Cell proliferation and thymocyte subset reconstitution in sublethally irradiated mice: compared kinetics of endogenous and intrathymically transferred progenitors.

AU Petit C; Ezine S
CS Institut National de la Sante et de la Recherche Medicale Unite 25, Centre National de la Recherche Scientifique Unite Associee 122, Hopital Necker, Paris, France.

SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1989 Jul) 86 (14) 5547-51.
Journal code: 7505876. ISSN: 0027-8424.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198908
ED Entered STN: 19900309
Last Updated on STN: 19970203
Entered Medline: 19890816

L8 ANSWER 31 OF 62 MEDLINE
AN 89296949
DN 89296949 Pubmed ID: 2500662
TI Positive selection of a T-cell subpopulation in the thymus in which it develops

AU Iwabuchi K; Negishi T; Arase H; Iwabuchi C; Ogasawara K; Good R A; Onoe K
CS Institute of Immunological Science, Hokkaido University, Japan.
AG05628 (NIAID)
A122360 (NDAID)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1989 Jul) 86 (13) 5089-93.
Journal code: 7505876. ISSN: 0027-8424.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198908
ED Entered STN: 19900309
Last Updated on STN: 19970203
Entered Medline: 19890810

L8 ANSWER 32 OF 62 MEDLINE
AN 90078997
DN 90078997 Pubmed ID: 2480382
TI A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.

AU Liou R S; Rosen E M; Fung M S; Sun W N; Sun C; Gordon W; Chang N T; Chang T W
CS Tenox Biosystems, Inc., Houston, TX 77025.
SO JOURNAL OF IMMUNOLOGY. (1989 Dec 15) 143 (12) 3967-75.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; AIDS
EM 199001
ED Entered STN: 19900328
Last Updated on STN: 19970203
Entered Medline: 19900119

L8 ANSWER 33 OF 62 MEDLINE
AN 89235187
DN 89235187 Pubmed ID: 2523932
TI Immune dysfunction associated with graft-vs-host reaction in mice transplanted across minor histocompatibility barriers. II. Reversible defect in T-dependent antibody responses.

AU Budhecha S; Hamilton B L
CS Department of Biological Structure, University of Washington, Seattle 98195.
NC CA-32757 (NCI)
CA-39889 (NCI)
SO JOURNAL OF IMMUNOLOGY. (1989 Jun 1) 142 (11) 3740-5.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198906
ED Entered STN: 19900306
Last Updated on STN: 19970203
Entered Medline: 19890622

L8 ANSWER 34 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89260094 EMBASE
DN 1989260094
TI Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia-epidermal cells.

AU Rosenberg A.S.; Katz S.I.; Singer A.
CS Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States
SO Journal of Immunology. (1989) 143/8 (2432-2436).
ISSN: 0022-1767 CODEN: JOIMAJ

CY United States
DT Journal
LA English
FS 026 Immunology, Serology and Transplantation
SL English

L8 ANSWER 35 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90010439 EMBASE
DN 1990010439
TI Positive and negative selection of T cell receptor V(beta.) domains controlled by distinct cell populations in the thymus.

AU Speiser D.; Lees R.K.; Hengartner H.; Zinkernagel R.M.; MacDonald H.R.
CS Institute of Pathology, University Hospital, 8091 Zurich, Switzerland
SO Journal of Experimental Medicine. (1989) 170/6 (2165-2170).
ISSN: 0022-1007 CODEN: JEMEXV

CY United States
DT Journal; Article
LA English
FS 026 Immunology, Serology and Transplantation
SL English

L8 ANSWER 36 OF 62 MEDLINE
AN 89156469
DN 89156469 Pubmed ID: 2466082
TI Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells.

AU Alters S E; Steinman L; Oi V T
CS Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
NC CA-09302 (NCI)
R01NS18235 (NINDS)

19871118

19890816

19900119

19900306

19900309

19900328

19970203

2480382

2500662

2501790

2523932

2985117R

3967-75

3740-5

5089-93

5547-51

T1 Mixed **chimerism** and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.
 AU Sharabi Y; Sachs D H
 CS Transplantation Biology Section, National Cancer Institute, Bethesda, Maryland 20892.
 SO JOURNAL OF EXPERIMENTAL MEDICINE. (1989 Feb 1) 169 (2) 493-502.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900308
 Last Updated on STN: 19950206
 Entered Medline: 19890221

L8 ANSWER 44 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989;257214 BIOSIS
 DN BR36:124438
 T1 COMPARISON OF RAT AND RAT-MOUSE CHIMERIC ANTIMURINE CD4 ANTIBODIES FOR USE IN IMMUNOTHERAPY.
 AU ALTERS S; STEINMAN L; OT V
 CS STANFORD UNIV. SCH. MED., STANFORD, CALIF. 94305.
 SO 73RD ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, NEW ORLEANS, LOUISIANA, USA, MARCH 19-23, 1989. FASEB (FED AM SOC EXP BIOL) J. (1989) 3 (3), A492.
 DT Conference
 FS CODEN: FAJOC. ISSN: 0892-6638.
 LA BR: OLD
 SL English

L8 ANSWER 45 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 89051469 EMBASE
 DN 1989051469
 T1 Persistence of the irradiated host component in thymocyte populations from bone marrow radiations **chimeras** infected with lymphocytic choriomeningitis virus.
 AU Lynch F.; Ceredig R.; Hartley D.; Doherty P.C.
 CS Department of Experimental Pathology, The John Curtin School of Medical Research, Canberra, ACT, Australia
 SO Cellular Immunology. (1989) 118/2 (482-490).
 DT United States
 CY Journal
 FS 026 Immunology, Serology and Transplantation
 DT 047 Virology
 LA English
 SL English

L8 ANSWER 46 OF 62 CAPLUS COPYRIGHT 2002 ACS
 AN 1990;116919 CAPLUS
 DN 112:116919
 T1 Production and properties of **chimeric antibody** molecules
 AU Shin, Seung Uon; Morrison, Sherie L.
 CS Mol. Biol. Inst., Univ. California, Los Angeles, CA, 90024, USA
 SO Methods Enzymol. (1989), 178(antibodies, Antigens, Mol. Mimicry), 459-76
 DT Journal
 LA English
 SL English

L8 ANSWER 47 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990;84459 BIOSIS
 DN BR38:40049

T1 IMMUNOPATHOLOGY OF MYCOSIS FUNGOIDES IN PATIENTS TREATED WITH CHIMERIC ANTI-CD4 ANTIBODY.
 AU WOOD G S; KNOX S; BINDI J; HOPPE R T; ABEL E A; WARNEKE R A; LEVY R
 CS STANFORD UNIV., STANFORD, CALIF., USA.
 SO 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF DERMATOPATHOLOGY, SAN FRANCISCO, CALIFORNIA, USA, NOVEMBER 29-DECEMBER 1, 1989. J CUTANEOUS PATHOL. (1989) 16 (5), 330.
 DT Conference
 FS CODEN: JCUPE. ISSN: 0303-6987.
 LA BR: OLD
 SL English

L8 ANSWER 48 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 89251146 EMBASE
 DN 1989251146
 T1 Monocyte function after bone marrow transplantation: Role of Ia⁺ monocytes in graft-versus-host disease.
 AU Bezrodn W.R.; Dansy R.
 CS Department of Medicine, Hematology/Oncology, University of the Witwatersrand, Johannesburg, South Africa
 SO Clinical Transplantation. (1989) 3/5 (264-268).
 DT Denmark
 CY Journal
 FS 025 Hematology
 DT 026 Immunology, Serology and Transplantation
 LA English
 SL English

L8 ANSWER 49 OF 62 MEDLINE
 AN 89203262 MEDLINE
 DN 89203262
 T1 Influence of the major histocompatibility complex on positive thymic selection of V beta 17a⁺ T cells.
 AU Blackman M A; Marrack P; Kappler J
 CS Howard Hughes Medical Institute, Denver, CO.
 SO SCIENCE. (1989 Apr 14) 244 (4901) 214-7.
 DT United States
 CY Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198905
 ED Entered STN: 19900306
 Last Updated on STN: 19900306
 Entered Medline: 19890512

L8 ANSWER 50 OF 62 MEDLINE
 AN 89080484 MEDLINE
 DN 89080484
 T1 Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multimor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
 AU Mayumi H; Good R A
 CS Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
 NC AG-05628 (NIA)
 SO JOURNAL OF EXPERIMENTAL MEDICINE. (1989 Jan 1) 169 (1) 213-38.
 DT United States
 CY Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals

DUPLICATE 25

DUPLICATE 24

EM 198902 Entered STN: 19900308
 ED Last Updated on STN: 19970203
 Entered Medline: 19890209

L8 ANSWER 51 OF 62 MEDLINE
 AN 91137503 PubMed ID: 2518657
 DN 91137503
 T1 Preferential expansion of Ly-1 B and CD4- CD8- T cells in the polyclonal lymphocyte responses to murine T. cruzi infection.
 AU Mignopoli P, Bandeira A, Pereira P, Mota Santos T, Coutinho A
 CS Department of Immunology, Pasteur Institute, Paris, France.
 SO INTERNATIONAL IMMUNOLOGY, (1989) 1 (2) 176-84.
 CY JOURNAL code: 8916182. ISSN: 0953-8178.
 DT English
 LA Journal, Article; (JOURNAL ARTICLE)
 FS English
 EM Priority Journals
 ED Entered STN: 19910412
 Last Updated on STN: 19910412
 Entered Medline: 19910322

L8 ANSWER 52 OF 62 MEDLINE
 AN 90007595 PubMed ID: 2793201
 DN 90007595
 T1 Donor and recipient specific tolerance in cells from semi-allogeneic, H-2 subregion compatible or fully allogeneic bone marrow chimeras attributable to clonal deletion.
 AU Onee K; Iwibuchi K; Iwibuchi C; Arase H; Hatakeyama S; Mambua P P; Fukushi N; Negishi I; Good R A; Ogasawara K
 CS Section of Pathology, Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
 NC AC05628 (NIA)
 SO AI22360 (NIAID)
 SO IMMUNOBIOLOGY, (1989 Jun) 179 (2-3) 172-89.
 CY JOURNAL code: 8002742. ISSN: 0171-2985.
 DT GERMANY, WEST: Germany, Federal Republic of
 LA Journal, Article; (JOURNAL ARTICLE)
 FS English
 EM Priority Journals
 ED Entered STN: 19900328
 Last Updated on STN: 19970203
 Entered Medline: 19891120

L8 ANSWER 53 OF 62 MEDLINE
 AN 89310351 PubMed ID: 2501444
 DN 89310351
 T1 Positive selection determines T cell receptor V beta 14 gene usage by CD8+ T cells.
 AU Liao N S; Maltzman J; Raulat D H
 CS Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139.
 NC CA-28900 (NCI)
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jul 1) 170 (1) 135-43.
 CY JOURNAL code: 2985109R. ISSN: 0022-1007.
 DT United States
 LA Journal, Article; (JOURNAL ARTICLE)
 FS English
 EM Priority Journals
 ED Entered STN: 19900309
 Last Updated on STN: 19970203

Entered Medline: 19890811

L8 ANSWER 54 OF 62 MEDLINE
 AN 89080475 PubMed ID: 2562846
 DN 89080475
 T1 Restricted tissue distribution of Mlsa determinants. Stimulation of Mlsa-reactive T cells by B cells but not by dendritic cells or macrophages.
 AU Webb S R; Okamoto A; Ron Y; Sprent J
 CS Research Institute of Scripps Clinic, La Jolla, California 92037.
 NC CA-25803 (NCI)
 CA-38355 (NCI)
 CA-41993 (NCI)
 +
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 1-12.
 CY JOURNAL code: 2985109R. ISSN: 0022-1007.
 DT United States
 LA Journal, Article; (JOURNAL ARTICLE)
 FS English
 EM Priority Journals
 ED Entered STN: 19900308
 Last Updated on STN: 19970203
 Entered Medline: 19890209

L8 ANSWER 55 OF 62 USPATFULL
 AN 88:74003 USPATFULL
 T1 Expression and diagnostic use of PENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
 Watanabe, Susan M., Seattle, WA, United States
 Cosand, Wesley L., Bothell, WA, United States
 McHardie, Susan, Seattle, WA, United States
 Travis, Bruce M., Seattle, WA, United States
 Genetic Systems Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 4784941 19881115
 AI US 1985-783299 19851002 (6)
 RLI Continuation-in-part of Ser. No. US 1985-721237, filed on 8 Apr 1985
 DT Utility
 FS Granted
 EM LN.CNT 835
 INCL INCLM: 435/005.000
 INCLS: 435/007.000; 435/070.000; 436/531.000; 436/811.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
 NCL NCIM: 435/005.000
 NCIS: 435/069.300; 435/974.000; 436/531.000; 436/811.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 930/221.000; 930/DIG.802; 930/DIG.811; 930/DIG.821
 IC [4]
 ICM: G01N033-545
 ICS: G01N033-53; C120001-70
 EXF 435/5; 435/7; 436/53; 436/811; 530/324-329
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 56 OF 62 USPATFULL
 AN 88:26041 USPATFULL
 T1 Biologically functional molecular chimeras
 Cohen, Stanley N., Menlo Park, CA, United States
 Boyer, Herbert W., Mill Valley, CA, United States
 PA The Board of Trustees of the Leland Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)
 PI US 4740470 19880426
 AI US 1984-602294 19840420 (6)
 RLI Continuation of Ser. No. US 1978-959288, filed on 9 Nov 1978, now

patented, Pat. No. US 4468464 which is a continuation of Ser. No. US 1976-687430, filed on 17 May 1976, now abandoned which is a continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974, now abandoned

DT Utility
FS Granted
LN.CNT 982
INCL INCLM: 435/172.300
INCLS: 435/091.000; 435/320.000; 435/240.200; 435/253.000; 935/027.000; 935/031.000; 935/032.000

NCL NCML: 435/006.000
NCLS: 435/091.400; 435/091.410; 435/252.300; 435/252.310; 435/252.330; 435/320.100; 435/488.000; 536/023.100

IC [4]
ICM: C12N015-00
ICS: C12N005-00; C12N001-20; C12P019-34
EXF 435/172.3; 435/91; 435/317; 435/253; 435/240; 435/320; 435/240.2; 935/27; 935/31; 935/32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 57 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN 1988:471673 CAPLUS
DN 109:71673
TI The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4
AU Landau, Nathaniel R.; Marton, Maria; Littman, Dan R.
CS Howard Hughes Med. Inst., Univ. California, San Francisco, CA, 94143, USA
SO Nature (London) (1988), 334(6178), 159-62
CODEN: NATUAS; ISSN: 0028-0836

DT Journal
LA English

L8 ANSWER 58 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 88208625 EMBASE
DN 1988208625
TI Cyclosporine-induced pseudo-graft-versus-host disease in the early post-cyclosporine period.
AU Beschoner W.E.; Shinn C.A.; Fischer A.C.; Santos G.W.; Hess A.D.
CS The Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21205, United States
SO Transplantation (1988) 46/2 SUPPL. (112S-117S).
ISSN: 0041-1337 CODEN: TRPLAU

CY United States
DT Journal
FS 005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA English
SL

L8 ANSWER 59 OF 62 MEDLINE
AN 88080506 MEDLINE
DN 88080506 PubMed ID: 3500795
TI Cyclosporine and the thymus: influence of irradiation and age on thymic immunopathology and recovery.
AU Beschoner W.E.; Di Gennaro K.A.; Hess A.D.; Santos G.W.
CS Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
NC A124319 (NIAID)
CA15396 (NCI)
CA28701 (NCI)
SO CELLULAR IMMUNOLOGY. (1987 Dec) 110 (2) 350-64.
CY Journal code: 1246405. ISSN: 0008-8749.
United States

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198802
ED Entered STN: 19900305
Last updated on STN: 19970203
Entered Medline: 19880202

L8 ANSWER 60 OF 62 USPATFULL
AN 86:71616 USPATFULL
TI Synthetic antigen for the detection of AIDS-related disease
IN Cosano, Wesley L., Bothell, WA, United States
PA Genetic Systems Corporation, Seattle, WA, United States (U.S. corporation)
PI US 4629783 19861216
AI US 1985-767303 19850819 (6)
R1I Continuation-in-part of Ser. No. US 1985-728052, filed on 29 Apr 1985, now abandoned

DT Utility
FS Granted
LN.CNT 841
INCL INCLM: 530/324.000
INCLS: 530/325.000; 530/326.000; 530/403.000
NCL NCML: 530/324.000
NCLS: 435/005.000; 435/068.100; 435/069.200; 435/961.000; 435/974.000; 530/325.000; 530/326.000; 530/403.000; 930/221.000; 930/DIG.802; 930/DIG.811; 930/DIG.821

IC [4]
ICM: C07K007-10
ICS: C07K017-00
EXF 260/112.SR; 530/324; 530/325; 530/326; 530/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 61 OF 62 USPATFULL
AN 84:48479 USPATFULL
TI Biologically functional molecular chimeras
IN Cohen, Stanley N., Menlo Park, CA, United States
AU Boyer, Herbert W., Mill Valley, CA, United States
PA The Board of Trustees of The Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)
PI US 4468464 19840828
AI US 1978-959288 19781109 (5)
R1I Continuation of Ser. No. US 1976-687430, filed on 17 May 1976, now abandoned which is a continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974, now abandoned

DT Utility
FS Granted
LN.CNT 885
INCL INCLM: 435/317.000
INCLS: 435/068.000; 435/253.000; 435/820.000; 435/172.300; 935/006.000; 935/029.000; 935/056.000; 935/060.000; 935/067.000; 935/068.000; 935/073.000; 935/084.000; 535/023.000
NCL NCML: 435/320.100
NCLS: 435/820.000

IC [3]
ICM: C12N001-00
ICS: C12N015-00; C12N001-20; C12P021-00
EXF 435/172; 435/68; 435/317; 435/91; 435/253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 62 OF 62 USPATFULL
AN 80:60508 USPATFULL
TI Process for producing biologically functional molecular chimeras
IN Cohen, Stanley N., Portola Valley, CA, United States

```

PA Boyer, Herbert W., Mill Valley, CA, United States
PI Board of Trustees of the Leland Stanford Jr. University, Stanford, CA,
  US 4237224
  19801202
AI US 1979-1021 19790104 (6)
RLI Continuation-in-part of Ser. No. US 1978-059288, filed on 9 Nov 1978,
  now Defensive Publication No. which is a continuation-in-part of Ser.
  No. US 1976-087430, filed on 17 May 1976, now abandoned which is a
  continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
  now Defensive Publication No.
DT Utility
FS Granted
LN CNT 983
INCL INCLM: 435/068.000
INCLS: 435/112.000; 435/231.000; 435/183.000; 435/317.000; 435/849.000;
  435/820.000; 435/091.000; 435/207.000; 260/112.500S; 260/027.000;
  435/212.000
NCL NCLM: 435/069.100
NCLS: 435/069.200; 435/069.300; 435/069.400; 435/069.500; 435/069.510;
  435/069.520; 435/069.600; 435/091.100; 435/091.400; 435/091.610;
  435/183.000; 435/207.000; 435/212.000; 435/231.000; 435/252.330;
  435/320.100; 435/820.000; 435/849.000; 530/311.000; 530/397.000;
  530/399.000; 530/808.000; 536/023.100
IC (1)
  ICM: C12P021-00
EXF 195/1: 195/28N; 195/28R; 195/112; 195/78; 195/79; 435/68; 435/172;
  435/231; 435/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)
FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
12:18:32 ON 25 JUN 2002
L1 0 S L1 NOT PY=>1991
L2 63 S CE9.1
L3 39370 S CHIMER? AND ANTIBOD?
L4 5562 S PRIVATE AND HUMAN AND L3
L5 1188 S CD4 AND L4
L6 4708 S L3 AND CD4
L7 121 S L6 NOT PY=>1991
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> treatment and 16
TREATMENT IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
L9 => s treat? and 16
L9 3420 TREAT? AND L6
L9 => s 19 not py=>1991
L9 4 FILES SEARCHED...
L10 44 L9 NOT PY=>1991
=> d 110 1-44

L10 ANSWER 1 OF 44 MEDLINE
AN 91185531 MEDLINE
DN 91185531 Pubmed ID: 2081787
TI The use of monoclonal antibodies for treatment of
  autoimmune disease.
  Steinman L
  Department of Neurology and Genetics, Stanford University, California
  94305.
SO JOURNAL OF CLINICAL IMMUNOLOGY, (1990 Nov) 10 (6 Suppl) 30S-38S;
  discussion 38S-39S. Ref: 21
  Journal code: 8102137. ISSN: 0271-9142.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
  General Review; (REVIEW)
  (REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199105
ED Entered STN: 19910526
  Last Updated on STN: 20000303
  Entered Medline: 19910509

L10 ANSWER 2 OF 44 MEDLINE
AN 91060926 MEDLINE
DN 91060926 Pubmed ID: 2147194
TI Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results
  in specific deletion of antigen-activated T cell clones.
  Bastos M G; Pankewycz O; Rubin-Kelley V E; Murphy J R; Strom T B
  Department of Medicine, Beth Israel Hospital, Harvard Medical School,
  Boston, MA 02115.
SO JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.
  Journal code: 2985117R. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199101
ED Entered STN: 19910222
  Last Updated on STN: 19910222
  Entered Medline: 19910107

L10 ANSWER 3 OF 44 MEDLINE
AN 91008471 MEDLINE
DN 91008471 Pubmed ID: 2211189
TI Cytotoxic and proliferative T-cell clones with antidonor reactivity from a
  patient transplanted for severe combined immunodeficiency disease.
  Keever C A; Flomenberg N; Gazzola M V; Pekle K; Yang S Y; Small T N;
  Collins N H; O'Reilly R J
  Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer
  Center, New York, New York.
NC CA-08748 (NCI)
  CA-33050 (NCI)
  CTST32CA09512-02 (DCRT)
SO HUMAN IMMUNOLOGY, (1990 Sep) 29 (1) 42-55.
  Journal code: 8010936. ISSN: 0198-8859.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199011
ED Entered STN: 19910117
  Last Updated on STN: 19960129
  Entered Medline: 19901116

L10 ANSWER 4 OF 44 MEDLINE
AN 91006312 MEDLINE
DN 91006312 Pubmed ID: 2209702
TI The requirement of intrathymic mixed chimerism and clonal

```

deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.
 Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Nomoto K
 CS Department of Immunology, Kyushu University, Fukuoka, Japan.
 SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1990 Sep) 20 (9) 2005-13.
 CY Journal code: 1273201. ISSN: 0014-2980.
 DT JOURNAL: Germany, Federal Republic of
 LA English
 FS Priority Journals
 EM 199011
 ED Entered STN: 19910117
 Last Updated on STN: 19910117
 Entered Medline: 19901121

L10 ANSWER 5 OF 44 MEDLINE
 AN 90315441 MEDLINE
 DN 90315441 PubMed ID: 2142440
 TI Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
 AU Champlin R; Ho W; Gajewski J; Feig S; Burnison W; Holley G; Greenberg P; Lee K; Schmid I; Giorgi J; +
 CS Division of Hematology/Oncology, UCLA Center for Health Sciences.
 NC CA-23175 (NCI)
 SO BLOOD, (1990 Jul 15) 76 (2) 418-23.
 CY Journal code: 7603509. ISSN: 0006-4971.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199008
 ED Entered STN: 19900921
 Last Updated on STN: 19900921
 Entered Medline: 19900817

L10 ANSWER 6 OF 44 MEDLINE
 AN 90278062 MEDLINE
 DN 90278062 PubMed ID: 1972161
 TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.
 AU Alters S E; Sakai K; Steinman L; Oi V T
 CS Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
 NC CA-39302 (NCI)
 SO JOURNAL OF IMMUNOLOGY, (1990 Jun 15) 144 (12) 4587-92.
 CY Journal code: 2985117R. ISSN: 0022-1767.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199007
 ED Entered STN: 19900824
 Last Updated on STN: 20000303
 Entered Medline: 19900718

L10 ANSWER 7 OF 44 MEDLINE
 AN 90212782 MEDLINE
 DN 90212782 PubMed ID: 2576640
 TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.
 AU Mahe G

CS Institut du Cancer et d'Immunogenetique, Immunitaires et Tumorales, Hopital Paul-Brousse, Villejuif, France.
 SO BIOMEDICINE AND PHARMACOTHERAPY, (1989) 43 (8) 551-61. Ref: 112
 CY Journal code: 8213293. ISSN: 0753-3322.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS General Review; (REVIEW) (REVIEW, TUTORIAL)
 EM 199005
 ED Entered STN: 19900622
 Last Updated on STN: 19970203
 Entered Medline: 19900514

L10 ANSWER 8 OF 44 MEDLINE
 AN 90078997 MEDLINE
 DN 90078997 PubMed ID: 2480382
 TI A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.
 AU Lion R S; Rosen E M; Fung M S; Sun W N; Sun C; Gordon W; Chang N T; Chang T W
 CS Tanox Biosystems, Inc., Houston, TX 77025.
 SO JOURNAL OF IMMUNOLOGY, (1989 Dec 15) 143 (12) 3967-75.
 CY Journal code: 2985117R. ISSN: 0022-1767.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals; AIDS
 EM 199001
 ED Entered STN: 19900328
 Last Updated on STN: 19970203
 Entered Medline: 19900119

L10 ANSWER 9 OF 44 MEDLINE
 AN 89176864 MEDLINE
 DN 89176864 PubMed ID: 2647894
 TI Induction of classical transplantation tolerance in the adult.
 AU Qin S X; Cobbold S; Benjamin R; Waldmann H
 CS Department of Pathology, University of Cambridge, United Kingdom.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Mar 1) 169 (3) 779-94.
 CY Journal code: 2985109R. ISSN: 0022-1007.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198904
 ED Entered STN: 19900306
 Last Updated on STN: 19900306
 Entered Medline: 19890424

L10 ANSWER 10 OF 44 MEDLINE
 AN 89156469 MEDLINE
 DN 89156469 PubMed ID: 2466082
 TI Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells.
 AU Alters S E; Steinman L; Oi V T
 CS Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
 NC CA-09302 (NCI)
 SO JOURNAL OF IMMUNOLOGY, (1989 Mar 15) 142 (6) 2018-23.
 CY Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198904
ED Entered STN: 19900306
Last Updated on STN: 19970203
Entered Medline: 19890417

L10 ANSWER 11 OF 44 MEDLINE
AN 89094246 MEDLINE
DN 89094246 Pubmed ID: 2562984
TI Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.
AU Shorabi Y; Sachs D H
CS Transplantation Biology Section, National Cancer Institute, Bethesda, Maryland 20892.
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Feb 1) 169 (2) 493-502.
CY United States
DT Journal code: 2985109R. ISSN: 0022-1007.
LA English
DT Journal; Article; (JOURNAL ARTICLE)
FS Priority Journals
EM 198902
ED Entered STN: 19900308
Last Updated on STN: 19950206
Entered Medline: 19890221

L10 ANSWER 12 OF 44 MEDLINE
AN 89080484 MEDLINE
DN 89080484 Pubmed ID: 2642528
TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus minor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
AU Mayumi H; Good R A
CS Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
NC AG-05628 (NIA)
AI-22360 (NIAID)
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 213-38.
CY United States
DT Journal code: 2985109R. ISSN: 0022-1007.
LA English
DT Journal; Article; (JOURNAL ARTICLE)
FS Priority Journals
EM 198802
ED Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19890209

L10 ANSWER 13 OF 44 MEDLINE
AN 89080475 MEDLINE
DN 89080475 Pubmed ID: 2562846
TI Restricted tissue distribution of Mlsa determinants. Stimulation of Mlsa-reactive T cells by B cells but not by dendritic cells or macrophages.
AU Webb S R; Okamoto A; Ron Y; Sprent J
CS Research Institute of Scripps Clinic, La Jolla, California 92037.
NC CA-25803 (NCI)
CA-38355 (NCI)
CA-41993 (NCI)
+
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 1-12.
Journal code: 2985109R. ISSN: 0022-1007.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198902
ED Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19890209

L10 ANSWER 14 OF 44 MEDLINE
AN 88080506 MEDLINE
DN 88080506 Pubmed ID: 3500795
TI Cyclosporine and the thymus: influence of irradiation and age on thymic immunopathology and recovery.
AU Beschornier W E; Di Gennaro K A; Hees A D; Santos G W
CS Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
NC A124319 (NIAID)
CA15396 (NCI)
CA28701 (NCI)
SO CELLULAR IMMUNOLOGY, (1987 Dec) 110 (2) 350-64.
CY United States
DT Journal code: 1246405. ISSN: 0008-8749.
LA English
DT Journal; Article; (JOURNAL ARTICLE)
FS Priority Journals
EM 198802
ED Entered STN: 19900305
Last Updated on STN: 19970203
Entered Medline: 19880202

L10 ANSWER 15 OF 44 CANCERLIT
AN 91060926 CANCERLIT
DN 91060926
TI Concomitant administration of hapten and IL-2-toxin (DAB86-IL-2) results in specific deletion of antigen-activated T cell clones.
AU Bastos M G; Pankewycz O; Rubin-Kelley V E; Murphy J R; Strom T B
CS Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02115.
SO JOURNAL OF IMMUNOLOGY, (1990). Vol. 145, No. 11, pp. 3535-9.
DT Journal code: 1FB. ISSN: 0022-1767.
FS MEDL; L; Abridged Index Medicus Journals; Priority Journals; Cancer Journals
LA English
OS MEDLINE 91060926
EM 199102

L10 ANSWER 16 OF 44 CANCERLIT
AN 90315441 CANCERLIT
DN 90315441
TI Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
AU Champalin R; Ho W; Gajewski J; Feig S; Burnison M; Holley G; Greenberg P; Lee K; Schmid I; Giorgi J; et al
CS Division of Hematology/Oncology, UCLA Center for Health Sciences.
NC CA-23175 (NCI)
RR00865 (NCRR)
SO BLOOD, (1990). Vol. 76, No. 2, pp. 418-23.
DT Journal code: A8G. ISSN: 0006-4971.
FS MEDL; L; Abridged Index Medicus Journals; Priority Journals; Cancer Journals
LA English

OS MEDLINE 90315441
EM 199009

L10 ANSWER 17 OF 44 CANCERLIT
AN 90212782
DN 90212782
TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.

AU Mathe G
CS Institut du Cancer et d'Immunogenetique, Immunitaires et Tumeurs, Hopital Paul-Brousse, Villejuif, France.
SO BIOMEDICINE AND PHARMACOTHERAPY, (1989). Vol. 43, No. 8, pp. 551-61.
DT Journal code: A59. ISSN: 0753-3322.
FS General Review; (REVIEW)
LA MED; L; Priority Journals
OS English
EM 199006

L10 ANSWER 18 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 91061964
DN 1991061964
TI The use of monoclonal antibodies for treatment of autoimmune disease.

AU Steinman L.
CS Department of Neurology and Genetics, Stanford University, Stanford, CA 94305, United States
SO Journal of Clinical Immunology, (1990) 10/6 SUPPL. (30S-39S).
CY ISSN: 0271-9142 CODEN: JCIMDO
DT United States
FS Journal; Conference Article
LA 026 Immunology, Serology and Transplantation
SL 037 Drug Literature Index
SL English

L10 ANSWER 19 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90256472
DN 1990256472
TI Cytotoxic and proliferative T-cell clones with antidonor reactivity from a patient transplanted for severe combined immunodeficiency disease.

AU Keever C.A.; Flomenberg N.; Gazzola M.V.; Pekle K.; Yang S.Y.; Small T.N.; Collins N.H.; O'Reilly R.J.
CS Div. Bone Marrow Transplant., Ohio State University, 410 W. 10th Avenue, Columbus, OH 43210, United States
SO Human Immunology, (1990) 29/1 (42-55).
CY ISSN: 0198-8859 CODEN: HUMIMQ
DT United States
FS Journal; Article
LA 026 Immunology, Serology and Transplantation
SL English

L10 ANSWER 20 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90231399
DN 1990231399
TI Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.

AU Champion R.; Ho W.; Gajewski J.; Feig S.; Burnson M.; Holley G.; Greenberg P.; Lee K.; Schmid I.; Giorgi J.; Yam P.; Peetz L.; Winston D.; Warner N.; Reichert T.
CS Section of Bone Marrow, Transplantation, MD Anderson Cancer Center, 1515

SO Holcombe Blvd., Houston, TX 77030, United States
Blood, (1990) 76/2 (418-423).
ISSN: 0006-4971 CODEN: BLOODM

CY United States
DT Journal; Article
FS 025 Hematology
LA 026 Immunology, Serology and Transplantation
SL English

L10 ANSWER 21 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90229954
DN 1990229954
TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.

AU Alters S.E.; Sakai K.; Steinman L.; Oi V.T.
CS Program in Cancer Biology, Stanford University School of Medicine, Stanford, CA 94305, United States
SO Journal of Immunology, (1990) 144/12 (4587-4592).
CY ISSN: 0022-1767 CODEN: JOIMA3
DT United States
FS Journal; Article
LA 026 Immunology, Serology and Transplantation
SL English

L10 ANSWER 22 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90078024
DN 1990078024
TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.

AU Mathe G.
CS Institut du Cancer et d'Immunogenetique and Departement des Maladies Sanguines, Immunitaires et Tumeurs, Hopital Paul-Brousse, 94800 Villejuif, France
SO Biomedicine and Pharmacotherapy, (1989) 43/8 (551-561).
CY ISSN: 0753-3322 CODEN: BIPHEX
DT France
FS Journal; Editorial
LA 016 Cancer
SL 026 Immunology, Serology and Transplantation
SL 037 Drug Literature Index
SL English

L10 ANSWER 23 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90012925
DN 1990012925
TI A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.

AU Lion R.-S.; Rosen E.M.; Fung M.S.C.; Sun W.N.C.; Sun C.; Gordon W.; Chang N.T.; Chang T.W.
CS Tanox Biosystems, Inc., 10301 Stella Link, Houston, TX 77025, United States
SO Journal of Immunology, (1989) 143/12 (3967-3975).
CY ISSN: 0022-1767 CODEN: JOIMA3
DT United States
FS Journal; Article
LA 026 Immunology, Serology and Transplantation
SL English

L10 ANSWER 24 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89081596
DN 89081596
EMBASE

DN 1999081596
TI Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. **Chimeric antibodies** lyse low-density CD4+ cells.

AU Alters S.E.; Steinman L.; Ol V.T.
CS Becton Dickinson Immunocytometry Systems, Mt. View, CA 94039, United States

SO Journal of Immunology, (1989) 142/6 (2018-2023).
ISSN: 0022-1767 CODEN: JOIMA3

CY United States
DT Journal
FS 026
LA English
SL English

L10 ANSWER 23 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89050647 EMBASE
DN 1989050647
TI Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preoperative regimen.

AU Sharabi Y.; Sachs D.H.
CS Transplantation Biology Section, Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States

SO Journal of Experimental Medicine, (1989) 169/2 (493-502).
ISSN: 0022-1007 CODEN: JEMEAU

CY United States
DT Journal
FS 025
LA English
SL English

L10 ANSWER 26 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89035554 EMBASE
DN 1989035554
TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multimajor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

AU Mayumi H.; Good R.A.
CS Division of Cardiovascular Surgery, Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan

SO Journal of Experimental Medicine, (1989) 169/1 (213-238).
ISSN: 0022-1007 CODEN: JEMEAU

CY United States
DT Journal
FS 025
LA English
SL English

L10 ANSWER 27 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89035539 EMBASE
DN 1989035539
TI Restricted tissue distribution of Mlsa determinants. Stimulation of Mlsa-reactive T cells by B cells but not by dendritic cells or macrophages.

AU Webb S.R.; Okamoto A.; Ron Y.; Sprent J.
CS Research Institute of Scripps Clinic, La Jolla, CA 92037, United States

SO Journal of Experimental Medicine, (1989) 169/1 (1-12).
ISSN: 0022-1007 CODEN: JEMEAU

CY United States
DT Journal

FS 026
LA English
SL English

L10 ANSWER 28 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:449174 BIOSIS
DN BA90:99814
TI CYTOTOXIC AND PROLIFERATIVE T-CELL CLONES WITH ANTIDONOR REACTIVITY FROM A PATIENT TRANSPLANTED FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE.

AU KEEVER C.A.; FLOMENBERG N.; GAZZOLA M.V.; PEKLE K.; YANG S.Y.; SMALL T.N.; COLLINS N.H.; O'REILLY R.J.
CS DIV. BONE MARROW TRANSPLANTATION, OHIO STATE UNIV., 1025N-DOAN HALL, 410 W. 10TH AVENUE, COLUMBUS, OHIO 43210.

SO HUM IMMUNOL., (1990) 29 (1), 42-55.
CODEN: HUMIMQ. ISSN: 0198-8859.

LA English
SL English

L10 ANSWER 29 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:417144 BIOSIS
DN BA90:77945
TI SELECTIVE DEPLETION OF CD8 POSITIVE T LYMPHOCYTES FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION.

AU CHAMPLIN R.; HO W.; GAJEWSKI J.; FELG S.; BURNISON M.; HOLLEY G.; GREENBERG P.; LEE K.; SCHMID T.; ET AL.
CS SECT. BONE MARROW TRANSPLANTATION, MD ANDERSON CANCER CENT., 1515 HOLCOMBE BLVD., HOUSTON, TEXAS 77030.

SO BLOOD, (1990) 76 (2), 418-423.
CODEN: BLOODM. ISSN: 0006-4971.

LA English
SL English

L10 ANSWER 30 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:380600 BIOSIS
DN BA90:67281
TI MECHANISMS OF ANTI-CD4-MEDIATED DEPLETION AND IMMUNOTHERAPY A STUDY USING A SET OF CHIMERIC ANTI-CD4 ANTIBODIES.

AU ALTERS S.E.; SAKAI K.; STEINMAN L.; OL V.T.
CS DEP. NEUROLOGY H-3160, STANFORD UNIVERSITY SCHOOL MEDICINE, STANFORD, CALIF. 94305-5235.

SO J IMMUNOL., (1990) 144 (12), 4587-4592.
CODEN: JOIMA3. ISSN: 0022-1767.

LA English
SL English

L10 ANSWER 31 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:92644 BIOSIS
DN BA89:51995
TI A CHIMERIC MOUSE-HUMAN ANTIBODY THAT RETAINS SPECIFICITY FOR HIV GP120 AND MEDIATES THE LYSIS OF HIV-INFECTED CELLS.

AU LIU R-S.; ROSEN E.R.; FUNG M.S.C.; SUN W.N.C.; SUN C.; GORDON W.; CHANG N.T.; CHANG T.W.
CS TANOX BIOSYSTEMS INC., 10301 STELLA LINK, HOUSTON, TEXAS 77025.

SO J IMMUNOL., (1989) 143 (12), 3967-3975.
CODEN: JOIMA3. ISSN: 0022-1767.

LA English
SL English

L10 ANSWER 32 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1990:84459 BIOSIS
DN BR38:40049
TI IMMUNOPATHOLOGY OF MYCOSIS FUNGIFORMIS MF PATIENTS TREATED WITH CHIMERIC ANTI-CD4 ANTIBODY.

AU WOOD G S; KNOX S; BINDL J; HOPPE R T; ABEL E A; WARNEK R A; LEVY R
CS STANFORD UNIV., STANFORD, CALIF., USA.
SO 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF DERMATOPATHOLOGY, SAN
FRANCISCO, CALIFORNIA, USA, NOVEMBER 29-DECEMBER 1, 1989. J CUTANEOUS
PATHOL. (1989) 16 (5), 330.
CODEN: JCUPEB. ISSN: 0303-6987.

DT Conference
FS BR; OLD
LA English

L10 ANSWER 33 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1989:224054 BIOSIS
DN BA87:115671

TI ANTIBODIES IN-VITRO CHIMERIC ANTIBODIES LYSE
COMPARISON OF RAT AND RAT-MOUSE CHIMERIC ANTI-MURINE CD4
ANTIBODIES IN-VITRO CHIMERIC ANTIBODIES LYSE

AU LOW-DENSITY CD4-POSITIVE CELLS.
ALTERS S E; STEINMAN L; OI V T
CS BECTON DICKINSON MONOCLONAL CENT., 2375 GARCIA AVE., MOUNTAIN VIEW, CALIF.
94039, USA.
SO J IMMUNOL. (1989) 142 (6), 2018-2023.
FS BA; OLD
LA English

L10 ANSWER 34 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1989:203337 BIOSIS
DN BA87:104241

TI MIXED CHIMERISM AND PERMANENT SPECIFIC TRANSPLANTATION TOLERANCE
INDUCED BY A NONLETHAL PREPARATIVE REGIMEN.

AU SHARABI Y; SACHS D H
CS NATL. CANCER INST., NATL. INST. HEALTH, BUILDING 10, ROOM 4B17, BETHESDA,
MD 20892, USA.
SO J EXP MED. (1989) 169 (2), 493-502.
FS CODEN: JEMEDV. ISSN: 0022-1007.
LA English

L10 ANSWER 35 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1989:136466 BIOSIS
DN BA87:11119

TI LONG-LASTING SKIN ALLOGRAFT TOLERANCE IN ADULT MICE INDUCED ACROSS FULLY
ALLOGENEIC MULTIMAJOR H-2 PLUS MINOR HISTOCOMPATIBILITY ANTIGEN
BARRIERS BY A TOLERANCE-INDUCED METHOD USING CYCLOPHOSPHAMIDE.

AU MAYUMI H; GOOD R A
CS DIV. CARDIOVASCULAR SURGERY, RES. INST. ANGIOCARDIOL., FAC. MED., KYUSHI
UNIV., 3-1-1 MAIDASHI, HIGASHI-KU, FUKUOKA 812, JPN.
SO J EXP MED. (1989) 169 (1), 213-238.
FS CODEN: JEMEDV. ISSN: 0022-1007.
LA English

L10 ANSWER 36 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1989:132635 BIOSIS
DN BA87:67288

TI RESTRICTED TISSUE DISTRIBUTION OF MIS-A DETERMINANTS STIMULATION OF
MIS-A-REACTIVE T CELLS BY B CELLS BUT NOT BY DENDRITIC CELLS OR
MACROPHAGES.

AU WEBB S R; OKAMOTO A; RON Y; SPRENT J
CS RES. INST. SCRIPPS CLIN., LA JOLLA, CALIF. 92037.
SO J EXP MED. (1989) 169 (1), 1-12.
FS CODEN: JEMEDV. ISSN: 0022-1007.
LA English

L10 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2002 ACS
AN 1990:629546 CAPLUS
DN 113:229546

TI Chimeric and mosaic antibodies to leu 3a antigen
IN Hinton, Robert; OI, Vernon T.
PA Becton, Dickinson and Co., USA
SO Eur. Pat. Appl., 12 pp.
CODEN: EPYXDM

DT Patent
LA English

FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 365209	A2	19900425	EP 1989-310415	19891011
EP 365209	A3	19900725		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LU, NL, SE				
JP 02238983	A2	19900921	JP 1989-270152	19891017
PRAI US 1988-260558		19881017		

L10 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2002 ACS
AN 1990:495863 CAPLUS
DN 113:95863

TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A
study using a set of chimeric anti-CD4
antibodies

AU Alters, Susan E.; Sakai, Koichiro; Steinman, Lawrence; OI, Vernon T.
CS Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
SO J. Immunol. (1990), 144(12), 4587-92
CODEN: JOIMA3; ISSN: 0022-1767

DT Journal
LA English

L10 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2002 ACS
AN 1990:116911 CAPLUS
DN 112:116911

TI A chimeric mouse-human antibody that retains
specificity for HIV gp120 and mediates the lysis of HIV-infected cells

AU Lion, Ruey Shyan; Rosen, Edward M.; Fung, Michael S. C.; Sun, William N.
CS Tanox Biosyst., Inc., Houston, TX, 77025, USA
SO J. Immunol. (1989), 143(12), 3967-75
CODEN: JOIMA3; ISSN: 0022-1767

DT Journal
LA English

L10 ANSWER 40 OF 44 USPATFULL
AN 90:67552 USPATFULL
TI Genes and their encoded proteins which regulate gene expression of the
interleukin-2 receptor and of human lymphotropic retroviruses
IN Cantor, Harvey I.; Wellesley, MA, United States
PA Patarca, Roberto, Brookline, MA, United States
Dana-Farber Cancer Institute, Boston, MA, United States (U.S.
corporation)

PI US 4952499 19900828
AT US 1988-154758 19880211 (7)
DT Utility
FS Granted
LN.CNT 1340

INCL INCLM: 435/172.300
INCLS: 435/091.000; 435/172.100; 435/320.000; 435/252.330; 435/240.200;
NCLM: 435/069.100; 435/320.000; 435/252.330; 435/240.200; 435/069.100
NCLS: 435/252.330; 435/320.100; 435/358.000; 435/372.300; 435/455.000;
536/023.520; 536/023.720; 536/024.100

IC (5)
 ICM: C12P021-00
 ICS: C12P021-02; C12P019-34; C12N015-00
 EXF 435/60; 435/70; 435/91; 435/172.3; 435/320; 530/350; 536/27;
 935/18; 935/32; 935/35; 935/58; 935/60; 935/70; 935/71
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 44 USPTAFULL
 AN 90:38221 USPTAFULL
 TI Detection and treatment of infectious and inflammatory lesions
 IN Hansen, Hans J., Westfield, NJ, United States
 PA Goldenberg, Milton D., Short Hills, NJ, United States
 PI US 4925648 19900515
 AI US 1988-226180 19880729 (7)
 DT Utility
 FS Granted
 LN.CNT 991
 INCL INCLM: 424/001.100
 INCLS: 424/009.000; 424/085.800; 424/085.910; 530/389.000; 530/402.000;
 NCL NCLM: 424/001.530
 NCLS: 252/001.000; 424/009.340; 424/136.100; 424/153.100; 424/154.100;
 424/178.100; 530/388.700; 530/388.730; 530/388.750; 530/389.600;
 530/391.300; 530/402.000; 530/866.000

IC (5)
 ICM: A61K049-02
 ICS: A61K049-00; A61K039-395
 EXF 424/1.1; 424/9; 424/85.91; 424/85.8; 530/387; 530/388; 530/389; 530/402;
 252/1

L10 ANSWER 42 OF 44 USPTAFULL
 AN 88:26041 USPTAFULL
 TI Biologically functional molecular chimeras
 IN Cohen, Stanley N., Menlo Park, CA, United States
 PA Boyer, Herbert W., Mill Valley, CA, United States
 PI US 4740470 19880426
 AI US 1984-602294 19840420 (6)
 DT Continuation of Ser. No. US 1978-959288, filed on 9 Nov 1978, now
 RLI patented, Pat. No. US 4468464 which is a continuation of Ser. No. US
 1976-687430, filed on 17 May 1976, now abandoned which is a
 continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 982
 INCL INCLM: 435/172.300
 INCLS: 435/091.000; 435/320.000; 435/240.200; 435/253.000; 935/027.000;
 935/031.000; 935/032.000
 NCL NCLM: 435/006.000
 NCLS: 435/091.400; 435/091.410; 435/252.300; 435/252.310; 435/252.330;
 435/320.100; 435/488.000; 536/023.100

IC (4)
 ICM: C12N015-00
 ICS: C12N005-00; C12N001-20; C12N001-00; C12P019-34
 EXF 435/172.3; 435/91; 435/317; 435/253; 435/240; 435/320; 435/240.2;
 935/27; 935/31; 935/32
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 44 USPTAFULL
 AN 84:48479 USPTAFULL
 TI Biologically functional molecular chimeras

IN Cohen, Stanley N., Menlo Park, CA, United States
 PA Boyer, Herbert W., Mill Valley, CA, United States
 PI US 4468464 19840828
 AI US 1978-959288 19781109 (5)
 RLI Continuation of Ser. No. US 1976-687430, filed on 17 May 1976, now
 abandoned which is a continuation-in-part of Ser. No. US 1974-520691,
 filed on 4 Nov 1974, now abandoned

DT Utility
 FS Granted
 LN.CNT 885
 INCL INCLM: 435/317.000
 INCLS: 435/068.000; 435/253.000; 435/820.000; 435/172.300; 935/006.000;
 935/029.000; 935/056.000; 935/060.000; 935/067.000; 935/068.000;
 935/073.000; 935/084.000; 535/023.000
 NCL NCLM: 435/320.100
 NCLS: 435/820.000

IC (3)
 ICM: C12N001-00
 ICS: C12N015-00; C12N001-20; C12P021-00
 EXF 435/172; 435/68; 435/317; 435/91; 435/253
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 44 OF 44 USPTAFULL
 AN 80:60508 USPTAFULL
 TI Process for producing biologically functional molecular chimeras
 IN Cohen, Stanley N., Portola Valley, CA, United States
 PA Boyer, Herbert W., Mill Valley, CA, United States
 PI US 4237224 19801202
 AI US 1979-1021 19790104 (6)
 RLI Continuation-in-part of Ser. No. US 1978-959288, filed on 9 Nov 1978,
 now Defensive Publication No. 1976-687430, filed on 17 May 1976, now abandoned which is a
 continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
 now Defensive Publication No.

DT Utility
 FS Granted
 LN.CNT 983
 INCL INCLM: 435/068.000
 INCLS: 435/172.000; 435/231.000; 435/183.000; 435/317.000; 435/849.000;
 435/820.000; 435/091.000; 435/207.000; 260/112.500S; 260/027.000;
 435/212.000
 NCL NCLM: 435/069.100
 NCLS: 435/069.200; 435/069.300; 435/069.400; 435/069.500; 435/069.510;
 435/069.520; 435/069.600; 435/091.100; 435/091.400; 435/091.410;
 435/183.000; 435/207.000; 435/212.000; 435/231.000; 435/252.330;
 435/320.100; 435/820.000; 435/849.000; 530/311.000; 530/397.000;
 530/399.000; 530/808.000; 536/023.100

IC (1)
 ICM: C12P021-00
 EXF 195/1; 195/28N; 195/28R; 195/112; 195/78; 195/79; 435/68; 435/172;
 435/231; 435/183
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)
 FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPTAFULL' ENTERED AT
 12:18:32 ON 25 JUN 2002

L1 63 S CE9.1
L2 0 S L1 NOT PY=>1991
L3 39370 S CHIMER? AND ANTI BOD?
L4 5562 S PRIMATE AND HUMAN AND L3
L5 1188 S CD4 AND L4
L6 4708 S L3 AND CD4
L7 121 S L6 NOT PY=>1991
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)
L9 3420 S TREAT? AND L6
L10 44 S L9 NOT PY=>1991
=> s l10 and gamma 4
L11 0 L10 AND GAMMA 4
=> s l10 and ce9gamma4pe
L12 0 L10 AND CE9GAMMA4PE
=> s ce9gamma4pe
L13 0 CE9GAMMA4PE
=> s l1s l10 and transplant rejection
MISSING OPERATOR L1s L10
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> s l10 and transplant reject?
L14 0 L10 AND TRANSPLANT REJECT?
=> s l1 and transplant reject?
L15 9 L1 AND TRANSPLANT REJECT?
=> d 1-9 l15

L15 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS
AN 1997:290112 CAPLUS
DN 126:263167
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabli; Newman, Roland A.; Reff, Mitchell E.
PA Idoc Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 154 pp.
CODEN: PIXKDZ
DT Patent
LA English
FNM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709351	A1	19970313	WO 1996-US14324	19960905
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GR, AU 6136310 A 20001024 US 1995-523894 19950906				
AU 9669162 A1 19970327 US 1995-523894 19950906				
AU 717674 B2 200000330 AU 1996-69162 19960905				
EP 854885 A1 19980729 EP 1996-929936 19960905				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9610404 A 19980706 BR 1996-10404 19960905				
JP 11514216 T2 19981207 JP 1996-511411 19960905				
NO 9800915 A 19980506 NO 1998-915 19980303				
PRA1 US 1995-523894 A 19950906				

US 1991-735064 B2 19910725
US 1992-856281 B2 19920323
US 1992-912292 B1 19920710
US 1995-379072 A2 19950125
US 1995-476237 A2 19950607
WO 1996-US14324 W 19960905
L15 ANSWER 2 OF 9 USPATFULL
AN 2002:85531 USPATFULL
TI POLYDITHIOCARBAMATE-CONFINING NON-TARGETING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
IN LAT, CHINE-SAN, ENCINITAS, CA, UNITED STATES
PI US 2002045573 A1 20020418
AI US 1999-409645 A1 19991001 (9)
RI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jun 1997, ABANDONED
PRA1 US 1996-25867P 19960910 (60)
DT Utility
FS APPLICATION
LN.CNT 1763
INCL INCLM: 514/006.000
INCLM: 514/044.000; 514/054.000; 514/476.000; 514/483.000; 530/403.000; 514/404.000; 514/405.000; 536/022.100; 536/123.100
NCLM: 514/006.000
NCL: 514/044.000; 514/054.000; 514/476.000; 514/483.000; 530/403.000; 514/404.000; 514/405.000; 536/022.100; 536/123.100
IC [7]
ICM: A61K038-16
ICS: A61K031-415; C07H021-00; A61K031-715; A01N043-04; A61K031-70; C07H001-00; C08H001-00; C07K017-00; A01N043-56; A61K031-27; A01N047-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 9 USPATFULL
AN 2001:202682 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassiliev, Vassil, San Diego, CA, United States
PA Medinov, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6316502 B1 20011113
AI US 2000-365666 20000505 (9)
RI Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743
DT Utility
FS GRANTED
LN.CNT 2591
INCL INCLM: 514/599.000
INCLM: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000; 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
NCLM: 514/599.000
NCL: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000; 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
IC [7]
ICM: A01N037-18
EXF 514/599; 514/707; 514/825; 514/838; 514/851; 514/861; 514/863; 514/885; 514/866; 514/903; 514/912; 514/925
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L15 ANSWER 4 OF 9 USPATFULL
AN 2001:173390 USPATFULL
TI Transgenic non-human animals for producing heterologous antibodies
IN Lomberg, Nils, Redwood City, CA, United States
Kay, Robert M., San Francisco, CA, United States
PA Genpharm International, Palo Alto, CA, United States (U.S. corporation)

PI US 6300129 B1 20011009
 AI US 1996-758417 19961202 (8)
 RLI Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996, now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US 1994-352332, filed on 7 Dec 1994, now patented, Pat. No. US 5625126 Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 5814318 Continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US 5789650 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
 DF Utility
 FS GRANTED
 LN.CNT 10030
 INCL INCLM: 435/326.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
 NCLM: 435/326.000
 NCL: 800/018.000
 NCLM: 435/326.000
 NCLS: 435/326.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
 800/018.000
 IC (7)
 ICM: C12N015-86
 ICS: C07K016-00; C12P021-00
 800/3; 800/6; 800/18; 435/326; 435/346; 435/354; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L15 ANSWER 5 OF 9 USPATFULL
 AN 2001:131342 USPATFULL
 TI Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 Vassilev, Vassil P., San Diego, CA, United States
 Wang, Tingmin, San Marcos, CA, United States
 Medinex, Inc., San Diego, CA, United States (U.S. corporation)
 PA PI US 6274627 B1 20010814
 AI US 1999-416619 19991012 (9)
 DT Utility
 FS GRANTED
 LN.CNT 2173
 INCL INCLM: 514/599.000
 INCLM: 514/706.000; 514/707.000
 NCLM: 514/599.000
 NCL: 514/706.000; 514/707.000
 IC (7)
 ICM: A61K031-16
 ICS: A61K031-095; A61K031-105
 514/599; 514/706; 514/707
 EXF 514/599; 514/706; 514/707
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L15 ANSWER 6 OF 9 USPATFULL
 AN 2001:102968 USPATFULL
 TI High affinity human antibodies and human antibodies against digoxin
 IN Londerberg, Nils, Woodside, CA, United States

PA Kay, Robert M., San Francisco, CA, United States
 PI US 6255458 B1 20010703
 AI US 1996-42353 19980313 (9)
 RLI Continuation-in-part of Ser. No. US 1996-758417, filed on 2 Dec 1996, now patented, Pat. No. US 1996-728463, filed on 10 Oct 1996, now patented, Pat. No. US 1995-544404, filed on 10 Oct 1995, now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US 1994-352332, filed on 7 Dec 1994, now patented, Pat. No. US 5625126 Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 5814318 Continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US 5789650 Continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 5633425 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
 DF Utility
 FS GRANTED
 LN.CNT 10059
 INCL INCLM: 530/388.150
 INCLM: 530/388.900; 435/326.000
 NCLM: 530/388.150
 NCL: 435/326.000; 530/388.900
 IC (7)
 ICM: C07K016-00
 ICS: 424/175.1; 435/326; 435/346; 435/345; 530/388.9; 530/388.15
 EXF 424/175.1; 435/326; 435/346; 435/345; 530/388.9; 530/388.15
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L15 ANSWER 7 OF 9 USPATFULL
 AN 2000:141878 USPATFULL
 TI Recombinant anti-CD4 antibodies for human therapy
 IN Hanna, Nabil, Olivenhain, CA, United States
 Newman, Roland Anthony, San Diego, CA, United States
 Reff, Mitchell Elliot, San Diego, CA, United States
 IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
 PA PI US 6136310 20001024
 AI US 1995-523894 19950906 (8)
 RLI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995, now patented, Pat. No. US 5756096 which is a continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
 DF Utility
 FS GRANTED
 LN.CNT 3398
 INCL INCLM: 424/154.100
 INCLM: 530/387.300; 424/133.100; 424/141.100
 NCLM: 424/154.100
 NCL: 424/133.100; 424/141.100; 530/387.300

IC [7]
 ICM: A61K039-395
 ICS: C12P021-08
 530/387.3; 424/133.1; 424/141.1; 424/154.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 9 USPATFULL
 AN 2000:95042 USPATFULL
 TI Therapeutic methods employing disulfide derivatives of dithiocarbamates
 IN and compositions useful therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 PA Vassilev, Vassil, San Diego, CA, United States
 PI US 6093743
 AI US 1998-103639 20000725
 DT Utility
 FS 19980623 (9)
 LN.CNT 2691
 INCL INCL: 514/599.000
 INCL: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
 514/866.000; 514/909.000; 514/912.000
 NCL NCLM: 514/599.000
 NCL: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
 514/866.000; 514/909.000; 514/912.000

IC [7]
 ICM: A61K031-16
 ICS: A61K031-095; A61K031-105
 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
 514/912
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 9 USPATFULL
 AN 2000:1981 USPATFULL
 TI Gamma-1 anti-human CD23 monoclonal antibodies
 IN Reff, Mitchell E., San Diego, CA, United States
 IN Kloeetzer, William S., Carlsbad, CA, United States
 PA Nakamura, Takehiko, Higashiyamato, Japan
 IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
 corporation)
 PI Seikagaku Corporation, Japan (non-U.S. corporation)
 AI US 6011138 20000104
 DT US 1997-803085 19970220 (8)
 FS Utility
 LN.CNT 2519
 INCL INCLM: 530/388.200
 INCL: 530/387.300; 530/388.200; 530/388.150; 530/388.730; 530/389.600;
 530/387.900; 424/133.100; 424/139.100; 424/142.100; 424/144.100;
 424/153.100; 424/173.100; 424/172.100; 435/007.240; 435/069.600;
 435/069.700; 435/070.210; 435/328.000; 435/331.000; 435/332.000;
 435/334.000; 435/343.100
 NCLM: 530/388.220
 NCL: 424/133.100; 424/139.100; 424/142.100; 424/144.100; 424/153.100;
 424/172.100; 424/173.100; 435/007.240; 435/069.600; 435/069.700;
 435/070.210; 435/328.000; 435/331.000; 435/332.000; 435/334.000;
 435/343.100; 530/387.300; 530/387.900; 530/388.150; 530/388.200;
 530/388.730; 530/389.600

IC [6]
 ICM: A61K039-395
 ICS: C12N005-12; C12N005-22; C07K016-28
 530/387.14; 530/387.3; 530/388.22; 530/388.2; 530/389.6; 424/643.1;
 424/133.1; 424/143.1; 424/139.1; 424/142.1; 424/144.1; 424/153.1;
 435/69.6; 435/69.7; 435/328; 435/334; 435/172.3; 435/7.24; 435/70.21;
 435/331; 435/343.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l1 and transplant reject?d his
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 'TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?D'
 The truncation symbol ? may be used only at the end of a search
 term. To specify a variable character within a word use 'i', e.g.,
 'woman' to search for both 'woman' and 'women'. Enter "HELP
 TRUNCATION" at an arrow prompt (=) for more information.

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
 12:18:32 ON 25 JUN 2002

L1 63 S CE9.1
 L2 0 S L1 NOT PY=>1991
 L3 39370 S CHIMER? AND ANTIBOD?
 L4 5562 S PRIMATE AND HUMAN AND L3
 L5 1188 S CD4 AND L4
 L6 4708 S L3 AND CD4
 L7 121 S L6 NOT PY=>1991
 L8 62 DUP REM L7 (59 DUPLICATES REMOVED)
 L9 3420 S TREAT? AND L6
 L10 44 S L9 NOT PY=>1991
 L11 0 S L10 AND GAMMA 4
 L12 0 S L10 AND CE9GAMMA4PE
 L13 0 S CE9GAMMA4PE
 L14 0 S L10 AND TRANSPLANT REJECT?
 L15 9 S L1 AND TRANSPLANT REJECT?

```

FILE 'MEDLINE' ENTERED AT 12:18:32 ON 25 JUN 2002

FILE 'CANCERLIT' ENTERED AT 12:18:32 ON 25 JUN 2002

FILE 'EMBASE' ENTERED AT 12:18:32 ON 25 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:18:32 ON 25 JUN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CAPLUS' ENTERED AT 12:18:32 ON 25 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:18:32 ON 25 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ce9.1
L1 63 CE9.1

=> s l1 not py=>1991
L2 4 FILES SEARCHED...
L2 0 L1 NOT PY=>1991

=> s chimere? and antibody?
L3 39370 CHIMER? AND ANTIBOD?

=> s primate and human and l3
L4 4 FILES SEARCHED...
L4 3562 PRIMATE AND HUMAN AND L3

=> s cd4 and l4
L5 1188 CD4 AND L4

=> s l3 and cd4
L6 4708 L3 AND CD4

=> s l6 not py=>1991
L7 4 FILES SEARCHED...
L7 121 L6 NOT PY=>1991

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> d his
(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)
FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
12:18:32 ON 25 JUN 2002
L1 63 S CE9.1
L2 0 S L1 NOT PY=>1991
L3 39370 S CHIMER? AND ANTIBOD?
L4 3562 S PRIMATE AND HUMAN AND L3
L5 1188 S CD4 AND L4
L6 4708 S L3 AND CD4
L7 121 S L6 NOT PY=>1991
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> d l1 1-63
L1 ANSWER 1 OF 63 MEDLINE

AN 2001465429 MEDLINE
DN 21401548 PubMed ID: 11510804
TI The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral
AU blood CD4+T-cells in asthma.
AU Kon O M; Sihra B S; Loh L C; Barkans J; Compton C H; Barnes N C; Larche M;
AY Kay A B
CS Department of Allergy and Clinical Immunology, Imperial College School of
CS Medicine, National Heart and Lung Institute, London, UK.
SO EUROPEAN RESPIRATORY JOURNAL, (2001 Jul) 18 (1) 45-52.
SO Journal code: 8803460. ISSN: 0903-1936.
CY Denmark
DT (CLINICAL TRIAL)
DT Journal; Article: (JOURNAL ARTICLE)
LA (RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
FS 200201
EM Entered STN: 20010821
ED Entered on STN: 20020124
ED Last Updated on STN: 20020102
ED Entered Medline: 20020102

ANSWER 2 OF 63 MEDLINE
L1 199294090 MEDLINE
AN 99294090 PubMed ID: 10367670
DN 99294090
TI Flow cytometry in the preclinical development of biopharmaceuticals.
TI Gossett K A; Narayanan P K; Williams D M; Gore E R; Herzyk D J; Hart T K;
AU Sellers T S
CS SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406,
CS USA.. kent.gossett@bphrd.com
SO TOXICOLOGIC PATHOLOGY, (1999 Jan-Feb) 27 (1) 32-7. Ref: 8
SO Journal code: 7905907. ISSN: 0192-6233.
CY United States
DT Journal; Article: (JOURNAL ARTICLE)
DT General Review; (REVIEW)
LA English
LA Priority Journals
FS 199907
EM Entered STN: 19990806
ED Last Updated on STN: 19990806
ED Entered Medline: 19990729

ANSWER 3 OF 63 MEDLINE
L1 1999012931 MEDLINE
AN 99012931 PubMed ID: 9798587
DN 99012931
TI Randomised, dose-ranging, placebo-controlled study of chimeric antibody to
TI CD4 (keliximab) in chronic severe asthma.
AU Kon O M; Sihra B S; Compton C H; Leonard T B; Kay A B; Barnes N C
CS London Chest Hospital, UK.
CS LANCET, (1998 Oct 31) 352 (9134) 1109-13.
SO Journal code: 2985213R. ISSN: 0140-6736.
CY ENGLAND: United Kingdom
CY (CLINICAL TRIAL)
DT Journal; Article: (JOURNAL ARTICLE)
DT (RANDOMIZED CONTROLLED TRIAL)
LA English
LA Abridged Index Medicus Journals: Priority Journals
FS 199811
EM Entered STN: 19990106
ED Last Updated on STN: 19990106
ED Entered Medline: 19981117

ANSWER 4 OF 63 MEDLINE
L1 1998339375 MEDLINE

```